Systematic Review: T-Cell–based Assays for the Diag An Update

Annals of Internal Medicine 149, 177 DOI: 10.7326/0003-4819-149-3-200808050-00241

Citation Report

#	Article	IF	CITATIONS
2	Update on clinical research of tuberculosis: a report from the European Respiratory Society. Expert Review of Respiratory Medicine, 2008, 2, 707-711.	1.0	0
3	T-cell interferon-Â release assays: can we do better?. European Respiratory Journal, 2008, 32, 1428-1430.	3.1	27
4	Possible miliary tuberculosis during adalimumab therapy with negative Â-IFN release assays. Rheumatology, 2008, 48, 319-320.	0.9	8
5	New Diagnostics for Latent and Active Tuberculosis: State of the Art and Future Prospects. Seminars in Respiratory and Critical Care Medicine, 2008, 29, 560-568.	0.8	71
6	Prognostic Value of a T-Cell–Based, Interferon-γ Biomarker in Children with Tuberculosis Contact. Annals of Internal Medicine, 2008, 149, 777.	2.0	138
7	Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country. Aids, 2008, 22, 2471-2479.	1.0	90
8	Improving T-Cell Assays for the Diagnosis of Latent TB Infection: Potential of a Diagnostic Test Based on IP-10. PLoS ONE, 2008, 3, e2858.	1.1	93
9	Use of Molecular Identification Analysis in a Case of Intra-familial Transmission of Tuberculosis. Tuberculosis and Respiratory Diseases, 2008, 65, 512.	0.7	1
10	Characterization and monitoring of host immune responses to infectious agents: what a future for microbiological diagnostics?. Microbiologia Medica, 2009, 24, .	0.3	0
11	The Diagnostic Value of Interferon-Î ³ Assay in Patients with Active Tuberculosis. Tuberculosis and Respiratory Diseases, 2009, 66, 13.	0.7	5
12	Prevalence and Risk Factors for Tuberculosis Infection among Hospital Workers in Hanoi, Viet Nam. PLoS ONE, 2009, 4, e6798.	1.1	48
13	IFNÎ ³ Response to Mycobacterium tuberculosis, Risk of Infection and Disease in Household Contacts of Tuberculosis Patients in Colombia. PLoS ONE, 2009, 4, e8257.	1.1	90
14	Within-Subject Variability of Interferon-g Assay Results for Tuberculosis and Boosting Effect of Tuberculin Skin Testing: A Systematic Review. PLoS ONE, 2009, 4, e8517.	1.1	171
15	III Diretrizes para Tuberculose da Sociedade Brasileira de Pneumologia e Tisiologia. Jornal Brasileiro De Pneumologia, 2009, 35, 1018-1048.	0.4	179
16	Esophageal Tuberculosis in a Patient on Maintenance Dialysis: Advantages of Interferon-Gamma Release Assay. Renal Failure, 2009, 31, 248-250.	0.8	5
17	Use of the T-SPOT. <i>TB</i> Assay to Detect Latent Tuberculosis Infection Among Rheumatic Disease Patients on Immunosuppressive Therapy. Journal of Rheumatology, 2009, 36, 546-551.	1.0	42
18	Early Diagnosis of Extrapulmonary Tuberculosis by a New Procedure Combining Broth Culture and PCR. Journal of Clinical Microbiology, 2009, 47, 1452-1457.	1.8	36
19	Utility of quantitative T-cell responses versus unstimulated interferon-Â for the diagnosis of pleural tuberculosis. European Respiratory Journal, 2009, 34, 1118-1126.	3.1	86

#	Article	IF	CITATIONS
20	Interferon gamma release assays for diagnosing active and latent tuberculosis. Expert Opinion on Medical Diagnostics, 2009, 3, 303-312.	1.6	4
21	Lupus Vulgaris Occurring in a Locus Minoris Resistentiae. Journal of Cutaneous Medicine and Surgery, 2009, 13, 313-316.	0.6	2
22	Cost-effectiveness of Tuberculosis Screening in Health Care Workers Is Not Robust. Archives of Internal Medicine, 2009, 169, 1336.	4.3	3
23	Quantitative lung T cell responses aid the rapid diagnosis of pulmonary tuberculosis. Thorax, 2009, 64, 847-853.	2.7	55
24	Comparison of Screening Procedures for <i>Mycobacterium tuberculosis</i> Infection Among Patients with Inflammatory Diseases. Journal of Rheumatology, 2009, 36, 1876-1884.	1.0	47
25	Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?. Aids, 2009, 23, 2507-2515.	1.0	38
26	Performance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised Patients. Chest, 2009, 136, 198-204.	0.4	137
27	Reactivation of Bovine Tuberculosis in Patient Treated with Infliximab, Switzerland. Emerging Infectious Diseases, 2009, 15, 1132-1133.	2.0	4
28	Short-Course Therapy with Daily Rifapentine in a Murine Model of Latent Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 1151-1157.	2.5	67
30	Within-Subject Variability and Boosting of T-Cell Interferon-Î ³ Responses after Tuberculin Skin Testing. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 49-58.	2.5	169
31	Interferon-gamma release assays and TB diagnosis. Drug and Therapeutics Bulletin, 2009, 47, 67-70.	0.3	1
32	Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in <i>Mycobacterium tuberculosis</i> –infected Individuals. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 724-733.	2.5	107
33	Serial Interferon Gamma Release Assay in Latent Tuberculosis Infection: Table 1. Laboratory Medicine, 2009, 40, 681-682.	0.8	0
34	Strengths and Weaknesses of Diagnostic Tools for Tuberculous Uveitis. Ocular Immunology and Inflammation, 2009, 17, 351-355.	1.0	86
35	Utility of QuantiFERON TB gold test in a south Indian patient population of ocular inflammation. Indian Journal of Ophthalmology, 2009, 57, 427.	0.5	47
36	Comment on: Possible miliary tuberculosis during adalimumab therapy with negative Â-IFN release assays. Rheumatology, 2009, 48, 1177-1178.	0.9	4
37	Short-Term Reproducibility of a Commercial Interferon Gamma Release Assay. Vaccine Journal, 2009, 16, 1170-1175.	3.2	66
38	Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs. European Respiratory Journal, 2009, 34, 702-710.	3.1	45

#	Article	IF	CITATIONS
39	Immunopathogenesis and Diagnosis of Tuberculosis and Tuberculosisâ€Associated Immune Reconstitution Inflammatory Syndrome during Early Antiretroviral Therapy. Journal of Infectious Diseases, 2009, 200, 1736-1745.	1.9	113
40	Gamma Interferon Release Assays for Diagnosis of Tuberculosis Infection in Immune-Compromised Children in a Country in Which the Prevalence of Tuberculosis Is Low. Journal of Clinical Microbiology, 2009, 47, 2355-2357.	1.8	25
41	Interferon-Â release assays for the diagnosis of active tuberculosis: sensible or silly?. European Respiratory Journal, 2009, 33, 1250-1253.	3.1	66
42	Preventing Tuberculosis Flare in Patients with Inflammatory Rheumatic Diseases Receiving Tumor Necrosis Factor-α Inhibitors in India — An Audit Report. Journal of Rheumatology, 2009, 36, 1414-1420.	1.0	38
43	Use of T Cell–Based Diagnosis of Tuberculosis Infection to Optimize Interpretation of Tuberculin Skin Testing for Child Tuberculosis Contacts. Clinical Infectious Diseases, 2009, 48, 302-312.	2.9	25
44	Is the QuantiFERON-TB Blood Assay a Good Replacement for the Tuberculin Skin Test in Tuberculosis Screening?. American Journal of Clinical Pathology, 2009, 132, 678-686.	0.4	24
45	Cost-effectiveness of Tuberculosis Screening in Health Care Workers Is Not Robust—Reply. Archives of Internal Medicine, 2009, 169, 1336.	4.3	0
46	Role of interferon-gamma release assays in healthcare workers. Journal of Hospital Infection, 2009, 73, 101-108.	1.4	18
47	Tuberculosis screening and follow-up of asylum seekers in Norway: a cohort study. BMC Public Health, 2009, 9, 141.	1.2	22
48	IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay. BMC Research Notes, 2009, 2, 19.	0.6	105
49	Mycobacterium tuberculosis in Solid Organ Transplant Recipients. American Journal of Transplantation, 2009, 9, S57-S62.	2.6	111
50	Interferon- \hat{I}^3 and Immunoglobulins in Latent Tuberculosis Infection. Archives of Medical Research, 2009, 40, 103-108.	1.5	12
51	Mycobacterium tuberculosis ESX-1 system-secreted protein ESAT-6 but not CFP10 inhibits human T-cell immune responses. Tuberculosis, 2009, 89, S74-S76.	0.8	43
53	Overcoming the global crisis: "Yes, we canâ€ , but also for TB … ?. European Journal of Immunology, 2009, 39, 2014-2020.	1.6	41
54	<i>Mycobacterium tuberculosis</i> infection in immunocompromised hosts: A diagnostic challenge. Liver Transplantation, 2009, 15, 834-837.	1.3	5
55	Usefulness of interferon-gamma release assays for diagnosing TB infection and problems with these assays. Journal of Infection and Chemotherapy, 2009, 15, 143-155.	0.8	65
56	The QuantiFERON®-TB-GOLD Assay for Tuberculosis Screening in Healthcare Workers: A Cost-Comparison Analysis. Lung, 2009, 187, 413-419.	1.4	22
57	Exploring the immune response against Mycobacterium tuberculosis for a better diagnosis of the infection. Archivum Immunologiae Et Therapiae Experimentalis, 2009, 57, 425-433.	1.0	16

#	Article	IF	CITATIONS
58	Diagnostic accuracy of Quantiferon TB test for patients with SLE and miliary tuberculosis. Rheumatology International, 2009, 29, 1395-1396.	1.5	3
59	Use of a T cell interferon gamma release assay in the investigation for suspected active tuberculosis in a low prevalence area. BMC Infectious Diseases, 2009, 9, 105.	1.3	18
60	New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response. BMC Infectious Diseases, 2009, 9, 182.	1.3	51
61	Screening for latent tuberculosis infection among undocumented immigrants in Swiss healthcare centres; a descriptive exploratory study. BMC Infectious Diseases, 2009, 9, 34.	1.3	26
62	A fatal case of spinal tuberculosis mistaken for metastatic lung cancer: recalling ancient Pott's disease. Annals of Clinical Microbiology and Antimicrobials, 2009, 8, 32.	1.7	27
63	In-hospital contact investigation among health care workers after exposure to smear-negative tuberculosis. Journal of Occupational Medicine and Toxicology, 2009, 4, 11.	0.9	28
64	Regions of Differences Encoded Antigens as Targets for Immunodiagnosis of Tuberculosis in Humans. Scandinavian Journal of Immunology, 2009, 70, 345-357.	1.3	31
65	The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nature Reviews Microbiology, 2009, 7, 845-855.	13.6	1,179
66	Latent Tuberculosis Infection in Travelers: Is There a Role for Screening Using Interferonâ€Gamma Release Assays?. Journal of Travel Medicine, 2009, 16, 352-356.	1.4	3
68	Role of interferon gamma release assays in tuberculosis. Respirology, 2009, 14, 156-158.	1.3	8
69	Increased levels of immunological markers in the respiratory tract but not in serum correlate with active pulmonary mycobacterial infection in mice. Clinical Microbiology and Infection, 2009, 15, 777-786.	2.8	4
70	Performance of Commercial Blood Tests for the Diagnosis of Latent Tuberculosis Infection in Children and Adolescents. Pediatrics, 2009, 123, e419-e424.	1.0	132
71	T-cell responses to the Mycobacterium tuberculosis-specific antigens in active tuberculosis patients at the beginning, during, and after antituberculosis treatment. Diagnostic Microbiology and Infectious Disease, 2009, 63, 43-51.	0.8	53
72	Quantitative evaluation of T-cell response after specific antigen stimulation in active and latent tuberculosis infection in adults and children. Diagnostic Microbiology and Infectious Disease, 2009, 65, 236-246.	0.8	34
73	Eliminating latent tuberculosis. Trends in Microbiology, 2009, 17, 183-188.	3.5	198
74	Diagnosis of Tuberculous Uveitis: Clinical Application of an Interferon-gamma Release Assay. Ophthalmology, 2009, 116, 1391-1396.	2.5	127
76	BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. Vaccine, 2009, 27, 6116-6120.	1.7	71
77	Comparative Performance of Tuberculin Skin Test, QuantiFERON-TB-Gold In Tube Assay, and T-Spot. TB Test in Contact Investigations for Tuberculosis. Chest, 2009, 135, 1010-1018.	0.4	153

#	Article	IF	CITATIONS
78	Management of TB during pregnancy, especially in high-risk communities. Expert Review of Obstetrics and Gynecology, 2009, 4, 555-563.	0.4	6
79	Novel and Improved Technologies for Tuberculosis Diagnosis: Progress and Challenges. Clinics in Chest Medicine, 2009, 30, 701-716.	0.8	118
80	IFN-Î ³ release assays in tuberculosis management in selected high-risk populations. Expert Review of Molecular Diagnostics, 2009, 9, 165-177.	1.5	15
81	Biomarkers of latent TB infection. Expert Review of Respiratory Medicine, 2009, 3, 387-401.	1.0	25
82	A case of Poncet disease diagnosed with interferon-Î ³ -release assays. Nature Reviews Rheumatology, 2009, 5, 643-647.	3.5	10
83	Comparison of Interferon-Gamma Release Assay Versus Tuberculin Skin Test for Latent Tuberculosis Screening in Hemodialysis Patients. Biotechnology and Biotechnological Equipment, 2009, 23, 1242-1246.	0.5	7
84	Clinical utility of the QuantiFERON-TB Gold In-Tube test for the diagnosis of active pulmonary tuberculosis. Scandinavian Journal of Infectious Diseases, 2009, 41, 818-822.	1.5	33
85	Tubercular Disease Caused by Bacillus of Calmette-Guérin as a Local Adjuvant Treatment of Relapsing Bladder Carcinoma. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 621-627.	0.7	8
86	Development and evaluation of a novel multiple-antigen ELISA for serodiagnosis of tuberculosis. Tuberculosis, 2009, 89, 278-284.	0.8	48
87	It is Time to Deal With Latent Tuberculosis Infection in Taiwan. Journal of the Formosan Medical Association, 2009, 108, 901-903.	0.8	7
88	Screening and Preventive Therapy for Tuberculosis. Clinics in Chest Medicine, 2009, 30, 827-846.	0.8	60
89	An Overview of Meta-analyses of Diagnostic Tests in Infectious Diseases. Infectious Disease Clinics of North America, 2009, 23, 225-267.	1.9	5
91	Annual Incidence of Latent Tuberculosis Infection among Newly Employed Nurses at a Tertiary Care University Hospital. Infection Control and Hospital Epidemiology, 2009, 30, 1218-1222.	1.0	40
92	Differentiating Intestinal Tuberculosis From Crohn's Disease: A Diagnostic Challenge. American Journal of Gastroenterology, 2009, 104, 1003-1012.	0.2	228
93	Novel screening tools for latent tuberculosis: time to leave an old friend?. Current Opinion in Rheumatology, 2009, 21, 238-243.	2.0	9
94	T-cell interferon-Î ³ release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings. Current Opinion in Pulmonary Medicine, 2009, 15, 188-200.	1.2	169
95	Interferon-gamma release assays for the diagnosis of TB pleural effusions: hype or real hope?. Current Opinion in Pulmonary Medicine, 2009, 15, 358-365.	1.2	48
96	Diagnosis of tuberculosis: principles and practice of using interferon-gamma release assays (IGRAs). Breathe, 2009, 5, 302-309.	0.6	2

#	Article	IF	CITATIONS
97	Granulomatous disorders of the nose and paranasal sinuses. Current Opinion in Otolaryngology and Head and Neck Surgery, 2009, 17, 23-27.	0.8	45
98	New diagnostic methods for tuberculosis. Current Opinion in Infectious Diseases, 2009, 22, 174-182.	1.3	61
99	Within-Subject Variability and Boosting of T-Cell Interferon-Î ³ Responses after Tuberculin Skin Testing. Yearbook of Medicine, 2009, 2009, 130-131.	0.1	0
100	Diagnosis and treatment of lung infection with nontuberculous mycobacteria. Current Opinion in Pulmonary Medicine, 2009, 15, 201-208.	1.2	45
101	Comparison of interferon gamma and interferon gamma-inducible protein-10 secretion in HIV–tuberculosis patients. Aids, 2010, 24, 323-325.	1.0	43
103	Commercial Interferon Gamma Release Assays Compared to the Tuberculin Skin Test for Diagnosis of Latent Mycobacterium tuberculosis Infection in Childhood Contacts in the Gambia. Pediatric Infectious Disease Journal, 2010, 29, 439-443.	1.1	51
104	Interferon-Î ³ release assays: new diagnostic tests for Mycobacterium tuberculosis infection, and their use in children. Current Opinion in Pediatrics, 2010, 22, 71-76.	1.0	51
105	Impact of Peripheral Lymphocyte Count on the Sensitivity of 2 IFNGAMMA. Release Assays, QFT-G and ELISPOT, in Patients with Pulmonary Tuberculosis. Internal Medicine, 2010, 49, 1849-1855.	0.3	36
106	2. Quanti-FERON for the Diagnosis of Tuberculosis The Journal of the Japanese Society of Internal Medicine, 2010, 99, 2703-2708.	0.0	0
107	New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Current Opinion in Pulmonary Medicine, 2010, 16, 1.	1.2	90
108	Tuberculin Skin Test and In Vitro Assays Provide Complementary Measures of Antimycobacterial Immunity in Children and Adolescents. Chest, 2010, 137, 1071-1077.	0.4	35
110	Comparison of same day versus delayed enumeration of TB-specific T cell responses. Journal of Infection, 2010, 60, 344-350.	1.7	10
111	Interferon-Gamma Release Assay in the Ascites: Early Hint for Diagnosis of Abdominal Tuberculosis. Infection, 2010, 38, 69-72.	2.3	5
113	The quest for biomarkers in tuberculosis. Drug Discovery Today, 2010, 15, 148-157.	3.2	105
114	Translational medicine as implementation science in the field of monitoring HIV and TB. New concepts emanating from resourceâ€poor countries. Cytometry Part B - Clinical Cytometry, 2010, 78B, 183-187.	0.7	4
115	Positive tuberculin skin tests in nursing home residents in Southern Taiwan. Archives of Gerontology and Geriatrics, 2010, 51, e129-e132.	1.4	3
116	Serial testing of interferon-γ-release assays for the diagnosis of latent tuberculosis in hemodialysis patients. Journal of Infection, 2010, 61, 144-149.	1.7	14
117	IFN-γ, but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis. Journal of Infection, 2010, 61, 133-143.	1.7	57

#	Article	IF	CITATIONS
118	Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers. BMC Infectious Diseases, 2010, 10, 220.	1.3	73
119	Rv1985c, a promising novel antigen for diagnosis of tuberculosis infection from BCG-vaccinated controls. BMC Infectious Diseases, 2010, 10, 273.	1.3	17
120	Performance of QuantiFERON-TB Cold In-Tube (QFTGIT) for the diagnosis of Mycobacterium tuberculosis (Mtb) infection in Afar Pastoralists, Ethiopia. BMC Infectious Diseases, 2010, 10, 354.	1.3	26
121	Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country. BMC Infectious Diseases, 2010, 10, 57.	1.3	66
122	Role of interferon-gamma release assays in the diagnosis of pulmonary tuberculosis in patients with advanced HIV infection. BMC Infectious Diseases, 2010, 10, 75.	1.3	33
123	Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulmonary Medicine, 2010, 10, 7.	0.8	79
124	Validity of interferon-Î ³ -release assays for the diagnosis of latent tuberculosis in haemodialysis patients. Clinical Microbiology and Infection, 2010, 16, 960-965.	2.8	42
125	Systematic Review and Metaâ€Analysis of TST Conversion Risk in Deployed Military and Longâ€Term Civilian Travelers. Journal of Travel Medicine, 2010, 17, 233-242.	1.4	23
126	Immunological Diagnosis of Tuberculosis Based on Recombinant Antigens ESAT-6 and CFP-10 in Children from an Endemic Area in Northeast Brazil. Scandinavian Journal of Immunology, 2010, 72, 460-468.	1.3	6
127	The value of an immune response to Mycobacterium tuberculosis in patients with chronic posterior uveitides revisited: utility of the new IGRAs. Eye, 2010, 24, 36-43.	1.1	33
128	Advances in the diagnosis of tuberculosis. Respirology, 2010, 15, 220-240.	1.3	130
129	Diagnostic usefulness of a T cell-based assay for latent tuberculosis infection in kidney transplant candidates before transplantation. Transplant Infectious Disease, 2010, 12, 113-119.	0.7	35
130	Bacterial and Fungal Diseases. , 2010, , 132-141.		0
131	Tuberculosis in Children: New diagnostic Blood Tests. Canadian Journal of Infectious Diseases and Medical Microbiology, 2010, 21, e111-e115.	0.7	5
132	Feasibility and Diagnostic Utility of Antigen-Specific Interferon-Î ³ Responses for Rapid Immunodiagnosis of Tuberculosis Using Induced Sputum. PLoS ONE, 2010, 5, e10389.	1.1	12
133	Sensitivity of the Quantiferon-Gold In-Tube Assay in Sputum Smear Positive TB Cases in Indonesia. PLoS ONE, 2010, 5, e12020.	1.1	6
134	Role of interferon-gamma release assays (IGRAs) for the screening of latent tuberculosis infection in patients candidates for TNF-α antagonist. Microbiologia Medica, 2010, 25, .	0.3	0
135	An Usefulness of <i>In Vitro</i> Interferon Gamma Assay for the Diagnosis of Latent Tuberculosis Infection in Middle- and High-School Students in Jeju-Shi, Korea. Tuberculosis and Respiratory Diseases, 2010, 68, 155.	0.7	2

#	Article	IF	CITATIONS
136	Saudi guidelines for testing and treatment of latent tuberculosis infection. Annals of Saudi Medicine, 2010, 30, 38.	0.5	39
137	High Prevalence of Latent Tuberculosis Infection in Dialysis Patients Using the Interferon-γ Release Assay and Tuberculin Skin Test. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1451-1457.	2.2	42
138	Interferon Gamma Release Assay in a 12-month-old BCG-Vaccinated Infant with Latent Tuberculosis Infection and Isolated <i>Mycobacterium fortuitum</i> : Table 1. Laboratory Medicine, 2010, 41, 662-664.	0.8	0
139	Latent Tuberculosis Detection by Interferon γ Release Assay during Pregnancy Predicts Active Tuberculosis and Mortality in Human Immunodeficiency Virus Type 1–Infected Women and Their Children. Journal of Infectious Diseases, 2010, 202, 1826-1835.	1.9	50
140	Updating prognostic parameters in COPD: the updated BODE index and ADO. Thorax, 2010, 65, 276-276.	2.7	0
141	A 100 year update on diagnosis of tuberculosis infection. British Medical Bulletin, 2010, 93, 69-84.	2.7	107
142	Tuberculosis treatment effect on T-cell interferon-Â responses to Mycobacterium tuberculosis-specific antigens. European Respiratory Journal, 2010, 36, 355-361.	3.1	83
143	Clinical management of tuberculosis and HIV-1 co-infection. European Respiratory Journal, 2010, 36, 1460-1481.	3.1	61
144	Tuberculous Uveitis. International Ophthalmology Clinics, 2010, 50, 19-39.	0.3	63
145	Comparison of two interferon-Â release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases. Annals of the Rheumatic Diseases, 2010, 69, 782-784.	0.5	37
146	Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection. European Respiratory Journal, 2010, 35, 619-626.	3.1	73
147	Interferon γ Responses to Mycobacterial Antigens Protect against Subsequent HIVâ€Associated Tuberculosis. Journal of Infectious Diseases, 2010, 202, 1265-1272.	1.9	29
148	Indeterminate results of a tuberculosis-specific interferon-Â release assay in immunocompromised patients. European Respiratory Journal, 2010, 35, 1179-1182.	3.1	38
150	Testalternativen zum Tuberkulin-Hauttest / Alternative assays to the tuberculin skin test. Laboratoriums Medizin, 2010, 34, 197-203.	0.1	0
151	Malnutrition and Helminth Infection Affect Performance of an Interferon γ–Release Assay. Pediatrics, 2010, 126, e1522-e1529.	1.0	85
152	Pairing QuantiFERON Gold In-Tube with Opt-Out HIV Testing in a Tuberculosis Contact Investigation in the Southeastern United States. AIDS Patient Care and STDs, 2010, 24, 539-543.	1.1	11
153	Ongoing tuberculosis transmission to children in Greenland. European Respiratory Journal, 2010, 36, 878-884.	3.1	22
154	A prospective large-scale study of methods for the detection of latent Mycobacterium tuberculosis infection in refugee children. Thorax, 2010, 65, 442-448.	2.7	64

#	Article	IF	Citations
155	Assessment of Imprecision in Gamma Interferon Release Assays for the Detection of Exposure to <i>Mycobacterium tuberculosis</i> . Vaccine Journal, 2010, 17, 596-601.	3.2	15
156	Tuberculosis contact investigation in low prevalence countries: a European consensus. European Respiratory Journal, 2010, 36, 925-949.	3.1	234
157	Optimizing the safety of biologic therapy for IBD. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 93-101.	8.2	46
158	Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. European Respiratory Journal, 2010, 36, 135-142.	3.1	119
159	Kinetics of a Tuberculosis-Specific Gamma Interferon Release Assay in Military Personnel with a Positive Tuberculin Skin Test. Vaccine Journal, 2010, 17, 937-943.	3.2	7
160	Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. European Respiratory Journal, 2010, 35, 1346-1353.	3.1	127
161	CCL5 participates in early protection against <i>Mycobacterium tuberculosis</i> . Journal of Leukocyte Biology, 2010, 87, 1153-1165.	1.5	93
162	Interpreting Tuberculin Skin Tests in a Population With a High Prevalence of HIV, Tuberculosis, and Nonspecific Tuberculin Sensitivity. American Journal of Epidemiology, 2010, 171, 1037-1045.	1.6	8
163	Hypoxia Induces an Immunodominant Target of Tuberculosis Specific T Cells Absent from Common BCG Vaccines. PLoS Pathogens, 2010, 6, e1001237.	2.1	35
164	Evaluation of Gamma Interferon Release Assays Using <i>Mycobacterium tuberculosis</i> Antigens for Diagnosis of Latent and Active Tuberculosis in <i>Mycobacterium bovis</i> BCG-Vaccinated Populations. Vaccine Journal, 2010, 17, 1985-1990.	3.2	44
165	Evidence-Based Comparison of Commercial Interferon-Î ³ Release Assays for Detecting Active TB. Chest, 2010, 137, 952-968.	0.4	346
166	Systematic review of interferon-gamma release assays in tuberculosis: focus on likelihood ratios. Thorax, 2010, 65, 271-276.	2.7	50
167	O uso da análise de libertação de gama interferão como auxiliar no controlo da tuberculose. Revista Portuguesa De Pneumologia, 2010, 16, S31-S35.	0.7	0
168	Do IFN-γ-release assays predict the risk of TB? New evidence from a study on patients with silicosis. Expert Review of Anti-Infective Therapy, 2010, 8, 1105-1108.	2.0	3
169	Evaluation of a modified interferon-gamma release assay for the diagnosis of latent tuberculosis infection in adult and paediatric populations that enables delayed processing. Scandinavian Journal of Infectious Diseases, 2010, 42, 845-850.	1.5	19
170	Evaluation of Quantitative IFN-γ Response for Risk Stratification of Active Tuberculosis Suspects. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 87-93.	2.5	32
171	T-Spot. <i>TB</i> Outperforms Tuberculin Skin Test in Predicting Tuberculosis Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 834-840.	2.5	61
172	Tuberculosis in the Global Aging Population. Infectious Disease Clinics of North America, 2010, 24, 751-768.	1.9	98

#	Article	IF	CITATIONS
173	Occupation-Related Respiratory Infections Revisited. Infectious Disease Clinics of North America, 2010, 24, 655-680.	1.9	4
174	Tuberculose. Revue Des Maladies Respiratoires Actualites, 2010, 2, 474-479.	0.0	0
177	New approaches in the diagnosis and treatment of latent tuberculosis infection. Respiratory Research, 2010, 11, 169.	1.4	67
178	Consensus Document on the Diagnosis, Treatment and Prevention of Tuberculosis. Archivos De Bronconeumologia, 2010, 46, 255-274.	0.4	21
179	The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. European Respiratory Journal, 2010, 36, 1185-1206.	3.1	444
180	Comparison of interferon-Â release assays and tuberculin skin test in predicting active tuberculosis (TB) in children in the UK: a paediatric TB network study. Archives of Disease in Childhood, 2010, 95, 180-186.	1.0	85
182	A statistical method was used for the meta-analysis of tests for latent TBÂin the absence of a gold standard, combining random-effect andÂlatent-class methods to estimate test accuracy. Journal of Clinical Epidemiology, 2010, 63, 257-269.	2.4	36
183	Interferon gamma release assays: principles and practice. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2010, 28, 245-252.	0.3	131
188	Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak. Respiratory Medicine, 2010, 104, 448-453.	1.3	36
189	Limited usefulness of QuantiFERON-TB Gold In-Tube® for monitoring anti-tuberculosis therapy. Respiratory Medicine, 2010, 104, 1551-1556.	1.3	23
190	Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI®. Vaccine, 2010, 28, 1106-1116.	1.7	119
191	Interferon-Î ³ release assay for tuberculosis screening of healthcare workers at a Korean tertiary hospital. Scandinavian Journal of Infectious Diseases, 2010, 42, 943-945.	1.5	20
193	Immune reconstitution inflammatory syndrome associated with Mycobacterium tuberculosis infection: a systematic review. International Journal of Infectious Diseases, 2010, 14, e283-e291.	1.5	41
194	Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet, The, 2010, 375, 1920-1937.	6.3	404
195	The HIV-associated tuberculosis epidemic—when will we act?. Lancet, The, 2010, 375, 1906-1919.	6.3	215
196	Tuberculosis pulmonar. Medicine, 2010, 10, 4587-4596.	0.0	1
197	The Population Dynamics and Control of Tuberculosis. Science, 2010, 328, 856-861.	6.0	559
199	Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infectious Diseases, The, 2010, 10, 803-812.	4.6	659

#	Article	IF	CITATIONS
200	A Proteome-Scale Identification of Novel Antigenic Proteins in <i>Mycobacterium tuberculosis</i> toward Diagnostic and Vaccine Development. Journal of Proteome Research, 2010, 9, 4812-4822.	1.8	43
201	Kinetics of the QuantiFERON®-TB Gold In-Tube test during treatment of patients with sputum smear-positive tuberculosis in relation to initial TST result and severity of disease. Scandinavian Journal of Infectious Diseases, 2010, 42, 650-657.	1.5	10
202	New Diagnostic Tests for Tuberculosis: Bench, Bedside, and Beyond. Clinical Infectious Diseases, 2010, 50, S173-S177.	2.9	77
203	Intraocular Tuberculosis. Ocular Immunology and Inflammation, 2010, 18, 281-291.	1.0	48
204	Cost Effectiveness of Interferon-Gamma Release Assay versus Chest X-Ray for Tuberculosis Screening of BCG-Vaccinated Elderly Populations. Molecular Diagnosis and Therapy, 2010, 14, 229-236.	1.6	17
205	Cost Effectiveness of Interferon-Gamma Release Assay for Tuberculosis Screening of Rheumatoid Arthritis Patients prior to Initiation of Tumor Necrosis Factor-α Antagonist Therapy. Molecular Diagnosis and Therapy, 2010, 14, 367-373.	1.6	28
206	Usefulness of anin-vitrotuberculosis interferon-Î ³ release assay (T-SPOT.TB) in the first-line check-up of uveitis patients. Annals of Medicine, 2010, 42, 546-554.	1.5	11
207	Tuberculin skin test and interferon-γ release assay show better correlation after the tuberculin â€̃window period' in tuberculosis contacts. Scandinavian Journal of Infectious Diseases, 2011, 43, 424-429.	1.5	14
208	Quantiferon test for tuberculosis screening in sarcoidosis patients. Scandinavian Journal of Infectious Diseases, 2011, 43, 728-735.	1.5	20
209	Interferon-Â release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. European Respiratory Journal, 2011, 37, 88-99.	3.1	490
210	Evaluation of a Tuberculosis Whole-Blood Interferon-Î ³ Chemiluminescent Immunoassay among Chinese Military Recruits. Molecular Diagnosis and Therapy, 2011, 15, 341-346.	1.6	9
211	Les tests diagnostiques de l'infection tuberculeuse : analyse critique. Revue Des Maladies Respiratoires Actualites, 2011, 3, 185-189.	0.0	1
214	Mycobacterial Sepsis and Multiorgan Failure Syndrome. Annual Update in Intensive Care and Emergency Medicine, 2011, , 531-542.	0.1	1
215	The BCG world atlas: a new, open-access resource for clinicians and researchers. Expert Review of Anti-Infective Therapy, 2011, 9, 559-561.	2.0	11
217	Latent Tuberculosis Infection in the United States. New England Journal of Medicine, 2011, 364, 1441-1448.	13.9	277
219	Pulmonary tuberculosis infection among workers in the informal public transport sector in Lima, Peru. Occupational and Environmental Medicine, 2011, 68, 163-165.	1.3	21
221	Cost-effectiveness of interferon-Î ³ release assay versus chest X-ray for tuberculosis screening of employees. American Journal of Infection Control, 2011, 39, e67-e72.	1.1	10
222	QuantiFERON-TB Gold Cut-off Value: Implications for the Management of Tuberculosis-Related Ocular Inflammation. American Journal of Ophthalmology, 2011, 152, 433-440.e1.	1.7	92

#	Article	IF	CITATIONS
223	Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-Î ³ release assay, and the development of active tuberculosis in HIV-seropositive persons. Diagnostic Microbiology and Infectious Disease, 2011, 69, 59-65.	0.8	27
224	Clinical utility of QuantiFERON-TB GOLD In-Tube and tuberculin skin test in patients with tuberculous pleural effusions. Diagnostic Microbiology and Infectious Disease, 2011, 71, 263-266.	0.8	11
225	Comparison of interferon gamma–inducible protein-10 and interferon gamma–based QuantiFERON TB Gold assays with tuberculin skin test in HIV-infected subjects. Diagnostic Microbiology and Infectious Disease, 2011, 71, 236-243.	0.8	23
226	Tuberculosis patients are characterized by a low–IFN-γ/high–TNF-α response to methylated HBHA produced in M. smegmatis. Diagnostic Microbiology and Infectious Disease, 2011, 71, 449-452.	0.8	15
227	Immunodiagnosis of Tuberculosis: a Dynamic View of Biomarker Discovery. Clinical Microbiology Reviews, 2011, 24, 792-805.	5.7	62
228	Is tuberculin skin testing reliable during anti–tumor necrosis factor-alfa therapy? AÂcase report and review of the literature. Journal of the American Academy of Dermatology, 2011, 65, 195-197.	0.6	39
232	ls screening immigrants for latent tuberculosis cost-effective?. Lancet Infectious Diseases, The, 2011, 11, 418-419.	4.6	17
233	Treatment of latent infection with Mycobacterium tuberculosis: update 2010. European Respiratory Journal, 2011, 37, 690-711.	3.1	104
234	Advances in the Diagnosis of Tuberculosis Infection. Archivos De Bronconeumologia, 2011, 47, 521-530.	0.4	13
235	Tuberculosis. Lancet, The, 2011, 378, 57-72.	6.3	670
236	Isoniazid preventive therapy in HIV infection. Lancet, The, 2011, 377, 1548-1550.	6.3	7
237	Sensitivity of Whole-Blood Interferon-Gamma Release Assay According to the Severity and the Location of Disease in Patients with Active Tuberculosis. Tuberculosis and Respiratory Diseases, 2011, 70, 125.	0.7	3
238	Deployment-Related Testing and Treatment for Latent Tuberculosis Infection, Part II. Military Medicine, 2011, 176, 1088-1092.	0.4	3
239	The effect of antituberculosis treatment on interferon-Î ³ release assay results. Monaldi Archives for Chest Disease, 2011, 75, 215-9.	0.3	5
241	Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive Agents. Annals of Laboratory Medicine, 2011, 31, 271-278.	1.2	31
242	The Tuberculin Skin Test versus QuantiFERON TB Gold® in Predicting Tuberculosis Disease in an Adolescent Cohort Study in South Africa. PLoS ONE, 2011, 6, e17984.	1.1	119
243	Risk Factors Associated with Positive QuantiFERON-TB Gold In-Tube and Tuberculin Skin Tests Results in Zambia and South Africa. PLoS ONE, 2011, 6, e18206.	1.1	42
244	Methylated HBHA Produced in M. smegmatis Discriminates between Active and Non-Active Tuberculosis Disease among RD1-Responders. PLoS ONE, 2011, 6, e18315.	1.1	72

#	Article	IF	CITATIONS
245	Longitudinal Analysis of QuantiFERON-TB Gold In-Tube in Children with Adult Household Tuberculosis Contact in South Africa: A Prospective Cohort Study. PLoS ONE, 2011, 6, e26787.	1.1	25
246	Novel M tuberculosis Antigen-Specific T-Cells Are Early Markers of Infection and Disease Progression. PLoS ONE, 2011, 6, e28754.	1.1	24
247	Role of the Quantiferon-TB Test in Ruling Out Pleural Tuberculosis: A Multi-Centre Study. International Journal of Immunopathology and Pharmacology, 2011, 24, 159-165.	1.0	13
248	Interferon-Gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Individuals: A Systematic Review and Meta-Analysis. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 230-238.	0.9	260
249	Interferon-Î ³ Release Assay for the Diagnosis of Latent Tuberculosis in Children Younger Than 5 Years of Age. Pediatric Infectious Disease Journal, 2011, 30, 866-870.	1.1	50
250	Interferon-Î ³ Release Assays: Are We Asking Too Much from What We Have Done?. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1733-1734.	2.5	0
251	Interferon-gamma release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Current Opinion in Rheumatology, 2011, 23, 377-384.	2.0	59
252	OPTIMIZING INTERPRETATION OF THE TUBERCULIN TEST USING AN INTERFERON-GAMMA RELEASE ASSAY AS A REFERENCE STANDARD. Pediatric Infectious Disease Journal, 2011, 30, 426-428.	1.1	14
253	The Utility of an Interferon Gamma Release Assay for Diagnosis of Latent Tuberculosis Infection and Disease in Children. Pediatric Infectious Disease Journal, 2011, 30, 694-700.	1.1	178
254	The Tuberculin Skin Test Is Unreliable in School Children BCC-vaccinated in Infancy and at Low Risk of Tuberculosis Infection. Pediatric Infectious Disease Journal, 2011, 30, 754-758.	1.1	19
257	Whole-Blood Interferon-Gamma Release Assay for Diagnosis of Tuberculous Lymphadenitis. Tohoku Journal of Experimental Medicine, 2011, 224, 189-193.	0.5	14
258	Diagnostic accuracy of Tâ€cell interferonâ€Î³ release assays in tuberculous pleurisy: A metaâ€analysis. Respirology, 2011, 16, 473-480.	1.3	50
259	T Regulatory Cells and Immune Activation in <i>Mycobacterium tuberculosis</i> Infection and the Effect of Preventive Therapy. Scandinavian Journal of Immunology, 2011, 73, 234-242.	1.3	49
260	Clinical applicability of Quantiferonâ€TBâ€Gold testing in psoriasis patients during longâ€ŧerm antiâ€TNFâ€alpha treatment: a prospective, observational study. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1572-1576.	1.3	44
261	Latent tuberculosis infection among new recruits to the army in Beijing, China in 2009. Apmis, 2011, 119, 377-384.	0.9	9
262	Immunological biomarkers of tuberculosis. Nature Reviews Immunology, 2011, 11, 343-354.	10.6	455
263	Influence of previous tuberculin skin test on serial IFN-Î ³ release assays. Tuberculosis, 2011, 91, 322-326.	0.8	27
264	Immune regulatory activities of early secreted antigenic target of 6-kD protein of Mycobacterium tuberculosis and implications for tuberculosis vaccine design. Tuberculosis, 2011, 91, S114-S118.	0.8	23

		CITATION R	EPORT	
#	Article		IF	Citations
265	Medical students at risk of nosocomial tuberculosis. Journal of Hospital Infection, 2011	., 77, 80-81.	1.4	9
266	Applications for T-cell epitope queries and tools in the Immune Epitope Database and A Resource. Journal of Immunological Methods, 2011, 374, 62-69.	nalysis	0.6	52
267	Detection of proliferative responses to ESAT-6 and CFP-10 by FASCIA assay for diagnos Mycobacterium tuberculosis infection. Journal of Immunological Methods, 2011, 370,		0.6	19
268	Immune-based diagnostics for TB in children: what is the evidence?. Paediatric Respirat 2011, 12, 9-15.	ory Reviews,	1.2	38
269	Tuberculosis screening before biologic therapy. Comment about the article entitled â€ interferon-gamma release assays in latent tuberculosis screening before TNF-α antago Liote H et al Joint Bone Spine, 2011, 78, 655-656.		0.8	3
271	Avances en el diagnÃ ³ stico de la infecciÃ ³ n tuberculosa. Archivos De Bronconeumolog 521-530.	ia, 2011, 47,	0.4	13
272	Indeterminate Results of QuantiFERON-TB Gold In-Tube Assay in Nonimmunosuppresse Archives of Medical Research, 2011, 42, 138-143.	2d Children.	1.5	15
273	Redefining latent tuberculosis. Future Microbiology, 2011, 6, 1021-1035.		1.0	24
274	Performance of tuberculin skin test and interferon gamma assay for the diagnosis of la tuberculosis infection in juvenile idiopathic arthritis. Clinical Rheumatology, 2011, 30,	tent 1189-1193.	1.0	19
275	Interferon-Î ³ release assay in the diagnosis of latent tuberculosis infection in arthritis pawer with tumor necrosis factor antagonists in Korea. Clinical Rheumatology, 2011, 30, 153		1.0	34
277	Latent tuberculosis: what the host "sees�. Immunologic Research, 2011, 50, 202	-212.	1.3	158
278	Clinical Evaluation of a Homemade Enzyme-Linked Immunospot Assay for the Diagnosi Tuberculosis in China. Molecular Biotechnology, 2011, 47, 18-25.	s of Active	1.3	9
279	Latent Tuberculosis in Children: Diagnosis and Management. Indian Journal of Pediatric 464-468.	s, 2011, 78,	0.3	14
280	Improving the Diagnosis of Tuberculosis: From QuantiFERON to New Techniques to Dia Tuberculosis Infections. Current HIV/AIDS Reports, 2011, 8, 153-163.	agnose	1.1	6
281	The Use of Interferon-Î ³ Release Assays for Tuberculosis Screening in International Trav Infectious Disease Reports, 2011, 13, 229-235.	elers. Current	1.3	4
282	Performance of whole-blood interferon-gamma release assay in patients admitted to th department with pulmonary infiltrates. BMC Infectious Diseases, 2011, 11, 107.	e emergency	1.3	13
283	IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculos Infectious Diseases, 2011, 11, 135.	is therapy. BMC	1.3	74
284	Improved sensitivity of an interferon-gamma release assay (T-SPOT.TBâ,,¢) in combinat tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-In Infectious Diseases, 2011, 11, 319.	ion with fection. BMC	1.3	28

#	Article	IF	CITATIONS
285	Community-based cross-sectional survey of latent tuberculosis infection in Afar pastoralists, Ethiopia, using QuantiFERON-TB Gold In-Tube and tuberculin skin test. BMC Infectious Diseases, 2011, 11, 89.	1.3	40
286	The clinical utility of tuberculin skin test and interferon-Î ³ release assay in the diagnosis of active tuberculosis among young adults: a prospective observational study. BMC Infectious Diseases, 2011, 11, 96.	1.3	22
287	Diagnosis of tuberculosis: the experience at a specialized diagnostic laboratory. Journal of Negative Results in BioMedicine, 2011, 10, 16.	1.4	5
288	Identification of a human immunodominant T-cell epitope of mycobacterium tuberculosis antigen PPE44. BMC Microbiology, 2011, 11, 167.	1.3	13
289	Concordance between tuberculin skin test and interferonâ€Î³ assay and interferonâ€Î³ response to mitogen in pediatric tuberculosis contacts. Pediatric Pulmonology, 2011, 46, 1225-1232.	1.0	22
290	Detection and management of latent tuberculosis in liver transplant patients. Liver Transplantation, 2011, 17, 306-314.	1.3	56
291	Latent tuberculosis infection screening for laboratory personnel using interferonâ€∳³ release assay and tuberculin skin test in Korea: an intermediate incidence setting. Journal of Clinical Laboratory Analysis, 2011, 25, 382-388.	0.9	11
292	Rapid diagnosis of tuberculous peritonitis by T cell-based assays on peripheral blood and peritoneal fluid mononuclear cells. Journal of Infection, 2011, 62, 462-471.	1.7	25
293	Interferon gamma release assay for differentiating tuberculosis among pneumonia cases in acute healthcare setting. Journal of Infection, 2011, 62, 440-447.	1.7	11
294	Reversion rates of QuantiFERON-TB Gold are related to pre-treatment IFN-gamma levels. Journal of Infection, 2011, 63, 48-53.	1.7	15
295	Ultrasensitive immunosensing of tuberculosis CFP-10 based on SPR spectroscopy. Sensors and Actuators B: Chemical, 2011, 156, 271-275.	4.0	46
296	Surrogate markers of infection: interrogation of the immune system. Biomarkers in Medicine, 2011, 5, 131-148.	0.6	4
297	Interferon-gamma release assays and childhood tuberculosis: systematic review and meta-analysis [Review article]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1018-1032.	0.6	214
298	Novel Developments in the Epidemic of Human Immunodeficiency Virus and Tuberculosis Coinfection. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 987-997.	2.5	29
299	Comparing the Tuberculin Skin Test and T-SPOT. <i>TB</i> Blood Test in Children. Pediatrics, 2011, 127, e31-e38.	1.0	55
300	New insights into gastrointestinal and hepatic granulomatous disorders. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 455-466.	8.2	42
301	Tuberculosis: evidence review for newly arriving immigrants and refugees. Cmaj, 2011, 183, E939-E951.	0.9	85
302	Within-Subject Variability of Mycobacterium tuberculosis-Specific Gamma Interferon Responses in German Health Care Workers. Vaccine Journal, 2011, 18, 1176-1182.	3.2	65

#	Article	IF	CITATIONS
303	Clinical Significance of Interleukin-2/Gamma Interferon Ratios in Mycobacterium tuberculosis-Specific T-Cell Signatures. Vaccine Journal, 2011, 18, 1395-1396.	3.2	24
304	Clinical Application and Limitations of Interferon-Â Release Assays for the Diagnosis of Latent Tuberculosis Infection. Clinical Infectious Diseases, 2011, 52, 1031-1037.	2.9	135
305	Point-Counterpoint: Should Interferon Gamma Release Assays Become the Standard Method for Screening Patients for Mycobacterium tuberculosis Infections in the United States?. Journal of Clinical Microbiology, 2011, 49, 2086-2092.	1.8	10
306	Diagnosing TB infection in children: analysis of discordances using in vitro tests and the tuberculin skin test. European Respiratory Journal, 2011, 37, 1166-1174.	3.1	38
307	Diagnosing Latent Tuberculosis in High-Risk Individuals: Rising to the Challenge in High-Burden Areas. Journal of Infectious Diseases, 2011, 204, S1168-S1178.	1.9	38
308	Interferon-gamma release assay for diagnosing <i>Mycobacterium tuberculosis</i> infections in patients with systemic lupus erythematosus. Lupus, 2011, 20, 792-800.	0.8	19
309	Comparison of Two Gamma Interferon Release Assays and Tuberculin Skin Testing for Tuberculosis Screening in a Cohort of Patients with Rheumatic Diseases Starting Anti-Tumor Necrosis Factor Therapy. Vaccine Journal, 2011, 18, 2102-2108.	3.2	57
310	Impact of Targeted Testing for Latent Tuberculosis Infection Using Commercially Available Diagnostics. Clinical Infectious Diseases, 2011, 53, 234-244.	2.9	14
311	Piecing the puzzle together: foreign-born tuberculosis in an immigrant-receiving country. European Respiratory Journal, 2011, 38, 895-902.	3.1	39
312	Two Immigrants with Tuberculosis of the Ear, Nose, and Throat Region with Skull Base and Cranial Nerve Involvement. Case Reports in Medicine, 2011, 2011, 1-5.	0.3	9
313	Pathogenesis, Immunology, and Diagnosis of Latent <i>Mycobacterium tuberculosis</i> Infection. Clinical and Developmental Immunology, 2011, 2011, 1-17.	3.3	195
314	Changing Concepts of "Latent Tuberculosis Infection―in Patients Living with HIV Infection. Clinical and Developmental Immunology, 2011, 2011, 1-9.	3.3	65
315	Interferon-Â release assays in tuberculosis contacts: is there a window period?. European Respiratory Journal, 2011, 37, 215-217.	3.1	31
316	Update on tuberculosis: TB in the early 21st century. European Respiratory Review, 2011, 20, 71-84.	3.0	37
317	Revival of the identification of cytotoxic T-lymphocyte epitopes for immunological diagnosis, therapy and vaccine development. Experimental Biology and Medicine, 2011, 236, 253-267.	1.1	35
318	Investigations in the diagnosis of uveitis. Expert Review of Ophthalmology, 2011, 6, 371-384.	0.3	0
319	Interferon-Î ³ Release Assays for Active Pulmonary Tuberculosis Diagnosis in Adults in Low- and Middle-Income Countries: Systematic Review and Meta-analysis. Journal of Infectious Diseases, 2011, 204, S1120-S1129.	1.9	241
320	Functional Capacity of <i>Mycobacterium tuberculosis</i> -Specific T Cell Responses in Humans Is Associated with Mycobacterial Load. Journal of Immunology, 2011, 187, 2222-2232.	0.4	305

#	Article	IF	CITATIONS
321	Double Screening for Latent Tuberculosis Infection in Patients Treated With Anti –Tumor Necrosis Factor α. Archives of Dermatology, 2011, 147, 1233.	1.7	0
322	Evidence-based clinical guidelines for immigrants and refugees. Cmaj, 2011, 183, E824-E925.	0.9	373
323	Usefulness of Interferon- γ Release Assays in the Diagnosis of Erythema Induratum. Archives of Dermatology, 2011, 147, 949.	1.7	12
324	Testing for Tuberculosis: The Roles of Tuberculin Skin Tests and Interferon Gamma Release Assays. Laboratory Medicine, 2011, 42, 11-16.	0.8	4
325	Screening of immigrants in the UK for latent tuberculosis. Expert Review of Respiratory Medicine, 2011, 5, 483-486.	1.0	2
326	T-SPOT.TB in the Diagnosis of Active Tuberculosis Among HIV-Infected Patients with Advanced Immunodeficiency. AIDS Research and Human Retroviruses, 2011, 27, 289-294.	0.5	15
327	Advances in the Diagnosis of Pulmonary Tuberculosis in HIV-Infected and HIV-Uninfected Children. Journal of Infectious Diseases, 2011, 204, S1151-S1158.	1.9	50
328	The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices. PLoS Medicine, 2011, 8, e1001012.	3.9	479
329	Negative and Positive Predictive Value of a Whole-Blood Interferon-Î ³ Release Assay for Developing Active Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 88-95.	2.5	275
330	Challenges in Diagnosing Latent Tuberculosis Infection in Patients Treated with Tumor Necrosis Factor Antagonists. Journal of Rheumatology, 2011, 38, 1234-1243.	1.0	46
331	The risk of tuberculosis in patients treated with TNF antagonists. Expert Review of Clinical Immunology, 2011, 7, 329-340.	1.3	46
332	Tuberculosis and Atypical Mycobacterial Infections. , 2011, , 228-247.		2
333	Tuberculosis in Antiretroviral Treatment Services in Resource-Limited Settings: Addressing the Challenges of Screening and Diagnosis. Journal of Infectious Diseases, 2011, 204, S1159-S1167.	1.9	112
334	Association of the level of IFN-Â produced by T cells in response to Mycobacterium tuberculosis-specific antigens with the size of skin test indurations among individuals with latent tuberculosis in a highly tuberculosis-endemic setting. International Immunology, 2012, 24, 71-78.	1.8	5
335	Heparin-Binding Hemagglutinin Induces IFN-γ ⁺ IL-2 ⁺ IL-17 ⁺ Multifunctional CD4 ⁺ T Cells during Latent but Not Active Tuberculosis Disease. Vaccine Journal, 2012, 19, 746-751.	3.2	26
336	Interferon-Gamma Release Assay Performance in Pulmonary and Extrapulmonary Tuberculosis. PLoS ONE, 2012, 7, e32652.	1.1	44
337	Tuberculosis Diagnostics in the New Millennium: Role in TB Identification and Control. Tuberculosis Research and Treatment, 2012, 2012, 1-2.	0.2	6
338	The Role of Interferon-gamma Release Assay in Tuberculosis Control. Arhiv Za Higijenu Rada I Toksikologiju, 2012, 63, 49-59.	0.4	5

#	Article	IF	CITATIONS
339	Miliary Tuberculosis Following Negative Latent Tuberculosis Infection Screening Prior to Tumor Necrosis Factor-α Antagonists: Implications for Management?. Journal of Rheumatology, 2012, 39, 1297-1298.	1.0	3
340	Clinical significance of an equivocal interferon Î ³ release assay result. British Journal of Ophthalmology, 2012, 96, 284-288.	2.1	14
341	Utility of QuantiFERON-TB Gold In-Tube testing in the detection of latent tuberculosis in liver transplant candidates. Egyptian Liver Journal, 2012, 2, 67-71.	0.3	2
342	The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. European Respiratory Journal, 2012, 40, 990-1013.	3.1	211
343	Multicytokine Detection Improves Latent Tuberculosis Diagnosis in Health Care Workers. Journal of Clinical Microbiology, 2012, 50, 1711-1717.	1.8	27
344	CD8 ⁺ T Cells Provide an Immunologic Signature of Tuberculosis in Young Children. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 206-212.	2.5	73
345	A pain in the neck. Gut, 2012, 61, 1582-1582.	6.1	0
346	Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay. Annals of the Rheumatic Diseases, 2012, 71, 231-237.	0.5	66
347	Diagnosing latent tuberculosis infection in haemodialysis patients: T-cell based assay (T-SPOT.TB) or tuberculin skin test?. Nephrology Dialysis Transplantation, 2012, 27, 1645-1650.	0.4	21
348	Specificity of the Tuberculin Skin Test and the T-SPOT. <i>TB</i> Assay Among Students in a Low–Tuberculosis Incidence Setting. Journal of American College Health, 2012, 60, 94-96.	0.8	9
349	Controversies and Unresolved Issues in Tuberculosis Prevention and Control: A Low-Burden-Country Perspective. Journal of Infectious Diseases, 2012, 205, S293-S300.	1.9	26
350	Levels of Interferon-Gamma Increase after Treatment for Latent Tuberculosis Infection in a High-Transmission Setting. Pulmonary Medicine, 2012, 2012, 1-6.	0.5	5
351	Immunosuppression Adversely Affects TST but Not IGRAs in Patients with Psoriasis or Inflammatory Musculoskeletal Diseases. International Journal of Rheumatology, 2012, 2012, 1-8.	0.9	17
352	Frequent Detection of Anti-Tubercular-Glycolipid-IgG and -IgA Antibodies in Healthcare Workers with Latent Tuberculosis Infection in the Philippines. Clinical and Developmental Immunology, 2012, 2012, 1-10.	3.3	12
353	The Use of Interferon Gamma Release Assays in the Diagnosis of Active Tuberculosis. Tuberculosis Research and Treatment, 2012, 2012, 1-4.	0.2	8
354	Consistency of <i>Mycobacterium tuberculosis</i> -Specific Interferon-Gamma Responses in HIV-1-Infected Women during Pregnancy and Postpartum. Infectious Diseases in Obstetrics and Gynecology, 2012, 2012, 1-7.	0.4	6
355	You can't always get what you want, but if you try sometimes (with two tests—TST and IGRA—for) Tj ETQq0 (0 o rgBT /C	Verlock 10 T

356	Influence of replacing tuberculin skin test with ex vivo interferon Î ³ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Annals of the Rheumatic Diseases, 2012, 71, 1783-1790.	0.	5	81	
-----	---	----	---	----	--

#	Article	IF	CITATIONS
357	Tuberculosis diagnostics for children in high-burden countries: what is available and what is needed. Paediatrics and International Child Health, 2012, 32, 30-37.	0.3	25
358	Discordance among Commercially Available Diagnostics for Latent Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 427-434.	2.5	52
359	Screening of healthcare workers for tuberculosis: development and validation of a new health economic model to inform practice. BMJ Open, 2012, 2, e000630.	0.8	10
361	Performance of Confirmatory Interferon-Î ³ Release Assays in School TB Outbreaks. Chest, 2012, 141, 983-988.	0.4	23
362	Long-Term Close Follow-up of Chorioretinal Lesions in Presumed Ocular Tuberculosis. European Journal of Ophthalmology, 2012, 22, 195-202.	0.7	11
363	Screening for Mycobacterium tuberculosis Using an Interferon-Gamma Release Assay. Journal of Public Health Management and Practice, 2012, 18, E19-E25.	0.7	4
364	Prevention and control of Pulmonary Tuberculosis: The role of IGRA (interferon-y release assay) tests in Occupational Surveillance Programs for Pulmonary Tuberculosis in an oilfield operation in a highly endemic area , 2012, , .		0
365	Interferon-Γ Release Assays for the Diagnosis and <i>Mycobacterium Tuberculosis</i> Infection in Children: A Systematic Review and Meta-Analysis. International Journal of Immunopathology and Pharmacology, 2012, 25, 557-564.	1.0	40
366	Systemic <i>Mycobacterium avium</i> Complex Infection During Antitumor Necrosis Factorâ€i± Therapy in Pediatric Crohn Disease. Journal of Pediatric Gastroenterology and Nutrition, 2012, 54, 294-296.	0.9	11
367	Relevance of Latent TB Infection in Areas of High TB Prevalence. Chest, 2012, 142, 761-773.	0.4	55
368	Serial Testing With TB Interferon-Î ³ Release Assays. Chest, 2012, 142, 1366-1368.	0.4	16
369	Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak. Epidemiology and Infection, 2012, 140, 1028-1035.	1.0	12
370	Performance of Quantiferon® for the diagnosis TB. Médecine Et Maladies Infectieuses, 2012, 42, 579-584.	5.1	2
371	Diagnosis and Management of Tuberculosis in Transplant Donors: A Donor-Derived Infections Consensus Conference Report. American Journal of Transplantation, 2012, 12, 2288-2300.	2.6	121
372	Is It Time to Replace the Tuberculin Skin Test With a Blood Test?. JAMA - Journal of the American Medical Association, 2012, 308, 241.	3.8	22
373	Immunodiagnosis of Tuberculosis: State of the Art. Medical Principles and Practice, 2012, 21, 4-13.	1.1	42
374	Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort. Infection, 2012, 40, 431-435.	2.3	31
375	Predictive Value of Recent QuantiFERON Conversion for Tuberculosis Disease in Adolescents. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1051-1056.	2.5	82

#	Article	IF	CITATIONS
376	Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax, 2012, 67, 62-70.	2.7	210
377	Tests for prediction of active tuberculosis. Lancet Infectious Diseases, The, 2012, 12, 6-8.	4.6	4
378	Management of children exposed to multidrug-resistant Mycobacterium tuberculosis. Lancet Infectious Diseases, The, 2012, 12, 469-479.	4.6	48
379	The diagnostic efficiency of QuantiFERONTB®-Gold test in the diagnosis of tuberculous pleurisy. International Journal of Mycobacteriology, 2012, 1, 180-184.	0.3	4
381	Identifying Predictors of Interferon-Î ³ Release Assay Results in Pediatric Latent Tuberculosis: A Protective Role of Bacillus Calmette-Guérin?. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 378-384.	2.5	98
383	Interferon-Î ³ release assays for prediction of tuberculosis. Lancet Infectious Diseases, The, 2012, 12, 584.	4.6	6
384	Super-paramagnetic iron oxide nanoparticles for use in extrapulmonary tuberculosis diagnosis. Clinical Microbiology and Infection, 2012, 18, E149-E157.	2.8	33
385	Skin Deep. New England Journal of Medicine, 2012, 366, 1336-1340.	13.9	5
386	Screening of tuberculosis before biologics. Médecine Et Maladies Infectieuses, 2012, 42, 1-4.	5.1	10
387	From the Arm to the Test Tube: Laboratory's New Role in Tuberculosis Testing. Clinical Microbiology Newsletter, 2012, 34, 117-125.	0.4	3
388	In routine UK hospital practice T-SPOT.TBâ,,¢ is useful in some patients with a modest pre-test probability of active tuberculosis. European Journal of Internal Medicine, 2012, 23, 363-367.	1.0	6
389	Predictive value of interferon-Î ³ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2012, 12, 45-55.	4.6	441
390	Contribution of Interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: A comparison of QuantiFERON-TB Gold In Tube, T-SPOT.TB and tuberculin skin test. BMC Infectious Diseases, 2012, 12, 169.	1.3	46
391	QuantiFERON-TB gold in-tube implementation for latent tuberculosis diagnosis in a public health clinic: a cost-effectiveness analysis. BMC Infectious Diseases, 2012, 12, 360.	1.3	14
392	Interferon-gamma release assays for the tuberculosis serial testing of health care workers: a systematic review. Journal of Occupational Medicine and Toxicology, 2012, 7, 6.	0.9	73
393	Diagnosis of latent tuberculosis infection in healthy young adults in a country with high tuberculosis burden and BCG vaccination at birth. BMC Research Notes, 2012, 5, 415.	0.6	26
394	Predictors for a positive QuantiFERON-TB-Gold test in BCG-vaccinated adults with a positive tuberculin skin test. Journal of Infection and Public Health, 2012, 5, 369-373.	1.9	5
395	The role of in vitro interferonÎ ³ -release assay in differentiating intestinal tuberculosis from Crohn's disease in China. Journal of Crohn's and Colitis, 2012, 6, 317-323.	0.6	35

#	Article	IF	CITATIONS
396	Tuberculosis in Transplantation: Diagnosis, Prevention, and Treatment. Current Infectious Disease Reports, 2012, 14, 650-657.	1.3	9
397	Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases who are candidates for biological therapy. GE Jornal Português De Gastrenterologia, 2012, 19, 290-299.	0.0	2
398	Circulating anti-double-stranded DNA antibody-secreting cells in patients with systemic lupus erythematosus: a novel biomarker for disease activity. Lupus, 2012, 21, 1284-1293.	0.8	18
399	Antigen-induced cytokine and chemokine release test for tuberculosis infection using adsorption of stimulated whole blood on filter paper and multiplex analysis. Scandinavian Journal of Clinical and Laboratory Investigation, 2012, 72, 204-211.	0.6	17
400	Diagnostic performance of multiplex cytokine and chemokine assay for tuberculosis. Tuberculosis, 2012, 92, 513-520.	0.8	38
401	Cost Effectiveness of Interferon-Gamma Release Assay for School-Based Tuberculosis Screening. Molecular Diagnosis and Therapy, 2012, 16, 181-190.	1.6	10
402	Interferon-gamma inducible protein 10 as a biomarker for active tuberculosis and latent tuberculosis infection in children: A case–control study. Scandinavian Journal of Infectious Diseases, 2012, 44, 256-262.	1.5	49
403	Interferon-Î ³ Release Assays for the Diagnosis of Tuberculosis and Tuberculosis Infection in HIV-Infected Adults: A Systematic Review and Meta-Analysis. PLoS ONE, 2012, 7, e32482.	1.1	132
404	Programmatic Impact of QuantiFERON-TB Gold In-Tube Implementation on Latent Tuberculosis Diagnosis and Treatment in a Public Health Clinic. PLoS ONE, 2012, 7, e36551.	1.1	28
405	Correlation of Mycobacterium Tuberculosis Specific and Non-Specific Quantitative Th1 T-Cell Responses with Bacillary Load in a High Burden Setting. PLoS ONE, 2012, 7, e37436.	1.1	33
406	Research Questions and Priorities for Tuberculosis: A Survey of Published Systematic Reviews and Meta-Analyses. PLoS ONE, 2012, 7, e42479.	1.1	24
407	TB Screening in Canadian Health Care Workers Using Interferon-Gamma Release Assays. PLoS ONE, 2012, 7, e43014.	1.1	30
408	Risk Stratification of Latent Tuberculosis Defined by Combined Interferon Gamma Release Assays. PLoS ONE, 2012, 7, e43285.	1.1	52
409	Within-Subject Interlaboratory Variability of QuantiFERON-TB Gold In-Tube Tests. PLoS ONE, 2012, 7, e43790.	1.1	38
410	Potential Role of M. tuberculosis Specific IFN-Î ³ and IL-2 ELISPOT Assays in Discriminating Children with Active or Latent Tuberculosis. PLoS ONE, 2012, 7, e46041.	1.1	58
411	Mtb-Specific CD27low CD4 T Cells as Markers of Lung Tissue Destruction during Pulmonary Tuberculosis in Humans. PLoS ONE, 2012, 7, e43733.	1.1	64
412	An Eight-Month-Old Child with Cervical Adenitis. Canadian Journal of Infectious Diseases and Medical Microbiology, 2012, 23, e53-e54.	0.7	0
413	Interferon-Gamma Release Assays for Screening of Health Care Workers in Low Tuberculosis Incidence Settings: Dynamic Patterns and Interpretational Challenges. Canadian Respiratory Journal, 2012, 19, 81-83.	0.8	21

#	Article	IF	CITATIONS
414	Clinical application of an in-house ELISPOT assay in patients with suspicious tuberculous uveitis and no signs of active tuberculosis. European Journal of Ophthalmology, 2012, 22, 808-813.	0.7	3
415	Multi-Drug/Extensively Drug Resistant Tuberculosis (Mdr/Xdr-Tb): Renewed Global Battle Against Tuberculosis?. , 2012, , .		4
416	Current management options for latent tuberculosis: a review. Infection and Drug Resistance, 2012, 5, 163.	1.1	19
417	Clinical Utility of Two Interferon-gamma Release Assays on Pleural Fluid for the Diagnosis of Tuberculous Pleurisy. Tuberculosis and Respiratory Diseases, 2012, 73, 143.	0.7	30
418	Serological diagnosis of tuberculosis using proteins expressed from the region of difference 1 (RD1) and RD2 of mycobacterium tuberculosis as antigens. African Journal of Microbiology Research, 2012, 6, 6698-6703.	0.4	1
419	Serial interferonâ€Î³ release assay in children with latent tuberculosis infection and children with tuberculosis. Pediatric Pulmonology, 2012, 47, 401-408.	1.0	15
420	Current developments and future perspectives for TB diagnostics. Future Microbiology, 2012, 7, 59-71.	1.0	14
421	Evaluation of interferon-gamma release assays for the diagnosis of tuberculosis: an updated meta-analysis. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 3127-3137.	1.3	34
422	Interferonâ€Î³ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti–tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis and Rheumatism, 2012, 64, 2068-2077.	6.7	81
423	Multiple organ tuberculosis of lung, pleura, and peritoneum in ankylosing spondylitis during adalimumab therapy. Rheumatology International, 2012, 32, 787-790.	1.5	11
424	Tuberculin reaction is not attenuated in patients with rheumatoid arthritis living in a region with intermediate burden of tuberculosis. Rheumatology International, 2012, 32, 1421-1424.	1.5	8
425	Mycobacterium bovis infection in a young Dutch adult: transmission from an elderly human source?. Medical Microbiology and Immunology, 2012, 201, 397-400.	2.6	4
426	Association of IFNGR2 gene polymorphisms with pulmonary tuberculosis among the Vietnamese. Human Genetics, 2012, 131, 675-682.	1.8	24
427	Dynamics of interferon-gamma release assay and cytokine profiles in blood and respiratory tract specimens from mice with tuberculosis and the effect of therapy. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 1195-1201.	1.3	16
428	Evaluation of various cytokines elicited during antigen-specific recall as potential risk indicators for the differential development of leprosy. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 1443-1451.	1.3	22
429	Interferon-gamma release assays for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. FEMS Immunology and Medical Microbiology, 2012, 65, 456-466.	2.7	76
430	A novel assay detecting recall response to MycobacteriumÂtuberculosis: Comparison with existing assays. Tuberculosis, 2012, 92, 321-327.	0.8	25
431	Questionable role of interferon-Î ³ assays for smear-negative pulmonary TB in immunocompromised patients. Journal of Infection, 2012, 64, 188-196.	1.7	28

#	Article	IF	CITATIONS
432	Interferon gamma and interferon gamma inducible protein-10 in detecting tuberculosis infection. Journal of Infection, 2012, 64, 573-579.	1.7	20
433	Role of Interferon Gamma Release Assays in Childhood Tuberculosis. Indian Journal of Pediatrics, 2012, 79, 250-252.	0.3	2
434	The effect of introducing IGRA to screen French healthcare workers for tuberculosis and potential conclusions for the work organisation. Journal of Occupational Medicine and Toxicology, 2013, 8, 12.	0.9	14
435	Implementation of an Interferon-Gamma Release Assay to Screen for Tuberculosis in Refugees and Immigrants. Journal of Immigrant and Minority Health, 2013, 15, 686-692.	0.8	6
436	Dynamic QuantiFERON Response in Psoriasis Patients Taking Long-Term Biologic Therapy. Dermatology and Therapy, 2013, 3, 73-81.	1.4	17
437	Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. The Cochrane Library, 2013, , CD007545.	1.5	76
438	Comparison of the tuberculin skin test and interferon-Î ³ release assay for the diagnosis of latent tuberculosis infection before kidney transplantation. Infection, 2013, 41, 103-110.	2.3	47
439	Antigen-specific CD4- and CD8-positive signatures in different phases of Mycobacterium tuberculosis infection. Diagnostic Microbiology and Infectious Disease, 2013, 75, 277-281.	0.8	71
440	Cost-Effectiveness of Latent Tuberculosis Screening Before Steroid Therapy for Idiopathic Nephrotic Syndrome in Children. American Journal of Kidney Diseases, 2013, 61, 22-32.	2.1	17
441	How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study. Digestive and Liver Disease, 2013, 45, 733-737.	0.4	12
442	Mycobacterium tuberculosis Infections in Solid Organ Transplantation. American Journal of Transplantation, 2013, 13, 68-76.	2.6	145
443	Apoptosis-associated biomarkers in tuberculosis: promising for diagnosis and prognosis prediction. BMC Infectious Diseases, 2013, 13, 45.	1.3	19
444	IFN-Î ³ release assay versus tuberculin skin test for monitoring TB infection in healthcare workers. Expert Review of Anti-Infective Therapy, 2013, 11, 37-48.	2.0	51
445	A diagnostic dilemma: infectious versus noninfectious multifocal choroiditis with panuveitis. Journal of Ophthalmic Inflammation and Infection, 2013, 3, 26.	1.2	16
446	T-cell-based IFN-Î ³ release assays for the diagnosis of latent tuberculosis infection: have they met our expectations?. Expert Review of Molecular Diagnostics, 2013, 13, 515-517.	1.5	3
448	Psoriasis, Anti-Tumor Necrosis Factor Therapy, and Tuberculosis: Report of Three Challenging Cases and Literature Review. Infectious Diseases and Therapy, 2013, 2, 59-73.	1.8	10
449	Weakly positive tests and chronologic variation of the QuantiFERON assay: A retrospective appraisal of usefulness. Tuberculosis, 2013, 93, 647-653.	0.8	10
450	Challenges with QuantiFERON-TB Gold Assay for Large-Scale, Routine Screening of U.S. Healthcare Workers. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1005-1010.	2.5	89

#	Article	IF	CITATIONS
451	Comparison of Cytomegalovirus (CMV) Enzyme-Linked Immunosorbent Spot and CMV Quantiferon Gamma Interferon-Releasing Assays in Assessing Risk of CMV Infection in Kidney Transplant Recipients. Journal of Clinical Microbiology, 2013, 51, 2501-2507.	1.8	82
452	Development of a test for bovine tuberculosis in cattle based on measurement of gamma interferon mRNA by realâ€ŧime PCR. Veterinary Record, 2013, 173, 117-117.	0.2	5
453	Diagnosis and treatment of latent tuberculosis infection: an update. Current Respiratory Care Reports, 2013, 2, 199-207.	0.6	17
454	Differential Diagnosis of Inflammatory Bowel Disease. , 2013, , 165-174.		0
455	Tuberculosis skin test, but not interferon-γ-releasing assays is affected by BCG vaccination in HIV patients. Journal of Infection, 2013, 66, 376-380.	1.7	13
456	Treatment of latent tuberculosis infection. Therapeutic Advances in Respiratory Disease, 2013, 7, 351-356.	1.0	19
457	Negative effect of immunosuppressive therapy in the performance of the QuantiFERON Gold In-Tube test in patients with immune-mediated inflammatory diseases. Clinical and Experimental Medicine, 2013, 13, 177-186.	1.9	27
458	Prevalence of latent tuberculosis infection in Sudan: a case–control study comparing interferon-γ release assay and tuberculin skin test. BMC Public Health, 2013, 13, 1128.	1.2	17
459	Poor agreement between interferon-gamma release assays and the tuberculin skin test among HIV-infected individuals in the country of Georgia. BMC Infectious Diseases, 2013, 13, 513.	1.3	24
461	Tuberculosis: Current state of knowledge. Respirology, 2013, 18, 1047-1055.	1.3	14
462	Cost effectiveness of the interferon-Â release assay for tuberculosis screening of hemodialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 682-688.	0.4	22
463	Tests for Latent Tuberculosis in People With ESRD: A Systematic Review. American Journal of Kidney Diseases, 2013, 61, 33-43.	2.1	50
464	Lipoproteins Are Major Targets of the Polyclonal Human T Cell Response to <i>Mycobacterium tuberculosis</i> . Journal of Immunology, 2013, 190, 278-284.	0.4	22
465	Detection and management of latent tuberculosis infections before biologic therapy for psoriasis. Journal of Dermatological Treatment, 2013, 24, 305-311.	1.1	28
467	Comparative study between using QuantiFERON and tuberculin skin test in diagnosis of Mycobacterium tuberculosis infection. The Egyptian Journal of Chest Diseases and Tuberculosis, 2013, 62, 137-143.	0.1	6
468	Cost effectiveness of high resolution computed tomography with interferon-gamma release assay for tuberculosis contact investigation. European Journal of Radiology, 2013, 82, 1353-1358.	1.2	9
469	Use of Quantiferon-TB-Gold in Tube® test for detecting latent tuberculosis in patients considered as candidates for anti-TNF therapy in routine clinical practice. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 76-81.	0.3	13
471	Tuberculosis. Primary Care - Clinics in Office Practice, 2013, 40, 743-756.	0.7	45

#	Article	IF	CITATIONS
472	Optimisation of a functional mycobacterial growth-inhibition assay to improve its suitability for infant TB vaccine studies. Journal of Immunological Methods, 2013, 394, 121-124.	0.6	7
473	Diagnostic and Management Strategies for Donor-derived Infections. Infectious Disease Clinics of North America, 2013, 27, 253-270.	1.9	10
474	Vitamin D and solar ultraviolet radiation in the risk and treatment of tuberculosis. Lancet Infectious Diseases, The, 2013, 13, 77-88.	4.6	73
475	Single-step QuantiFERON screening of adult contacts: a prospective cohort study of tuberculosis risk. Thorax, 2013, 68, 240-246.	2.7	36
476	IGRAs – The gateway to T cell based TB diagnosis. Methods, 2013, 61, 52-62.	1.9	58
477	Functional profile of CD4+ and CD8+ T cells in latently infected individuals and patients with active TB. Tuberculosis, 2013, 93, 155-166.	0.8	48
478	Possible antistenotic effect of tranilast in a patient with small bowel tuberculosis to prevent intestinal obstruction due to stenosis progression by antituberculous chemotherapy. Digestive Endoscopy, 2013, 25, 333-335.	1.3	2
479	Perspectives of Quantiferon TB Gold test among Indian practitioners: a survey. Journal of Ophthalmic Inflammation and Infection, 2013, 3, 9.	1.2	7
480	Diagnosis and treatment of latent infection with <i><scp>M</scp>ycobacterium tuberculosis</i> . Respirology, 2013, 18, 205-216.	1.3	40
481	Interferon-Î ³ release assays versus tuberculin skin test for targeting people for tuberculosis preventive treatment: An evidence-based review. Journal of Infection, 2013, 66, 381-387.	1.7	32
482	Comparison of whole-blood interferon-Î ³ assay and flow cytometry for the detection of tuberculosis infection. Journal of Infection, 2013, 66, 338-345.	1.7	19
483	Conversion rates of an interferon-Î ³ release assay and the tuberculin skin test in the serial monitoring of healthcare workers. Infection, 2013, 41, 511-516.	2.3	9
484	Intracellular cytokine detection by fluorescence-activated flow cytometry: Basic principles and recent advances. Methods, 2013, 61, 30-38.	1.9	81
485	Evaluation of interferon- \hat{I}^3 release assay in the diagnosis of osteoarticular tuberculosis. Diagnostic Microbiology and Infectious Disease, 2013, 76, 309-313.	0.8	11
486	IFN-Î ³ Release Assays in the Diagnosis of Latent Tuberculosis Infection among Immunocompromised Adults. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 422-431.	2.5	99
487	Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment. Journal of Infection, 2013, 66, 346-356.	1.7	33
488	Interferon-Î ³ Release Assays and Tuberculin Skin Testing for Diagnosis of Latent Tuberculosis Infection in Healthcare Workers in the United States. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 77-87.	2.5	182
490	Tuberculosis Screening Before and During Treatment with Tumor Necrosis Factor Antagonists: Something Old, Something New. Journal of Rheumatology, 2013, 40, 1938-1940.	1.0	9

#	Article	IF	CITATIONS
491	Acceptability of interferon-gamma release assays among healthcare workers who receive routine employee tuberculosis testing. International Journal of Occupational and Environmental Health, 2013, 19, 319-324.	1.2	5
492	Does an interferon-gamma release assay change practice in possible latent tuberculosis?. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 139-146.	0.2	4
493	Tuberculosis vaccines. , 2013, , 789-811.		5
494	Mycobacterium tuberculosis Region of Difference (RD) 2 Antigen Rv1985c and RD11 Antigen Rv3425 Have the Promising Potential To Distinguish Patients with Active Tuberculosis from M. bovis BCG-Vaccinated Individuals. Vaccine Journal, 2013, 20, 69-76.	3.2	14
495	Tuberculosis and the military. Journal of the Royal Army Medical Corps, 2013, 159, 190-199.	0.8	7
496	High Rates of <i>Mycobacterium tuberculosis</i> among Socially Marginalized Immigrants in Low-Incidence Area, 1991–2010, Italy. Emerging Infectious Diseases, 2013, 19, 1437-1445.	2.0	17
497	Changes in Tuberculin Skin Test Positivity Over 20 Years in Periurban Shantytowns in Lima, Peru. American Journal of Tropical Medicine and Hygiene, 2013, 89, 507-515.	0.6	22
498	Interferon-gamma treatment kinetics among patients with active pulmonary tuberculosis. Nigerian Medical Journal, 2013, 54, 376.	0.6	3
499	Risk Factors for Tuberculosis. Pulmonary Medicine, 2013, 2013, 1-11.	0.5	379
500	Lower prevalence of tuberculosis infection in BCG vaccinees: a cross-sectional study in adult prison inmates. Thorax, 2013, 68, 263-268.	2.7	37
501	High Incidence of Tuberculosis Infection in Rheumatic Diseases and Impact for Chemoprophylactic Prevention of Tuberculosis Activation during Biologics Therapy. Vaccine Journal, 2013, 20, 842-847.	3.2	16
502	Evaluation of QuantiFERON microtube, using 0.9 mL blood, for diagnosing tuberculosis infection. European Respiratory Journal, 2013, 41, 909-916.	3.1	4
503	Accelerated colorimetric immunosensing using surface-modified porous monoliths and gold nanoparticles. Science and Technology of Advanced Materials, 2013, 14, 044403.	2.8	6
504	Interferon-Gamma Release Assays versus Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection: An Overview of the Evidence. Pulmonary Medicine, 2013, 2013, 1-11.	0.5	107
505	Interferon-Î ³ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists:in vivoandin vitroanalysis. British Journal of Dermatology, 2013, 169, 1133-1140.	1.4	22
506	Biomarkers of tuberculosis: a research roadmap. Biomarkers in Medicine, 2013, 7, 349-362.	0.6	18
507	Effect of Prolonged Incubation Time on Results of the QuantiFERON TB Gold In-Tube Assay for Diagnosis of Latent Tuberculosis Infection. Vaccine Journal, 2013, 20, 1377-1380.	3.2	7
508	Predictive value of interferon-gamma release assays for postpartum active tuberculosis in HIV-1-infected women. International Journal of Tuberculosis and Lung Disease, 2013, 17, 1552-1557.	0.6	8

#	Article	IF	CITATIONS
509	Cost-effectiveness of interferon-gamma release assay for entry tuberculosis screening in prisons. Epidemiology and Infection, 2013, 141, 2224-2234.	1.0	13
510	Clinical review: Tuberculosis on the intensive care unit. Critical Care, 2013, 17, 240.	2.5	41
511	Feasibility of the Interferon-Î ³ Release Assay for the Diagnosis of Genitourinary Tuberculosis in an Endemic Area. Korean Journal of Urology, 2013, 54, 123.	1.2	8
513	Updating a Tuberculosis Surveillance Program. Workplace Health and Safety, 2013, 61, 271-278.	0.7	0
514	Immunologic Diagnosis of Active Tuberculosis. Infection and Chemotherapy, 2013, 45, 110.	1.0	0
515	Screening for Latent TB Infection in a Psoriasis Patient with History of BCG Vaccination and Exposure to TB Prior to Treatment with an Anti-TNF-α Agent. Psoriasis Forum, 2013, 19a, 191-193.	0.1	0
516	How Methodologic Differences Affect Results of Economic Analyses: A Systematic Review of Interferon Gamma Release Assays for the Diagnosis of LTBI. PLoS ONE, 2013, 8, e56044.	1.1	23
517	Soluble Markers of the Toll-Like Receptor 4 Pathway Differentiate between Active and Latent Tuberculosis and Are Associated with Treatment Responses. PLoS ONE, 2013, 8, e69896.	1.1	21
518	Impairment of IFN-Gamma Response to Synthetic Peptides of Mycobacterium tuberculosis in a 7-Day Whole Blood Assay. PLoS ONE, 2013, 8, e71351.	1.1	5
519	Two-Step Tuberculin Skin Testing in School-Going Adolescents with Initial 0-4 Millimeter Responses in a High Tuberculosis Prevalence Setting in South India. PLoS ONE, 2013, 8, e71470.	1.1	6
520	Tuberculosis Screening by Tuberculosis Skin Test or QuantiFERON®-TB Gold In-Tube Assay among an Immigrant Population with a High Prevalence of Tuberculosis and BCG Vaccination. PLoS ONE, 2013, 8, e82727.	1.1	23
521	Recombinant ESAT-6-CFP10 Fusion Protein Induction of Th1/Th2 Cytokines and FoxP3 Expressing Treg Cells in Pulmonary TB. PLoS ONE, 2013, 8, e68121.	1.1	22
522	Diagnostic Evaluation of Tuberculosis. , 2013, , .		2
523	Safe Re-administration of Tumor Necrosis Factor-alpha (TNFα) Inhibitors in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Who Developed Active Tuberculosis on Previous Anti-TNFα Therapy. Journal of Korean Medical Science, 2014, 29, 38.	1.1	13
524	Interferon-Gamma Assay in Combination with Tuberculin Skin Test Are Insufficient for the Diagnosis of Culture-Negative Pulmonary Tuberculosis. PLoS ONE, 2014, 9, e107208.	1.1	14
525	Identification of a 251 Gene Expression Signature That Can Accurately Detect M. tuberculosis in Patients with and without HIV Co-Infection. PLoS ONE, 2014, 9, e89925.	1.1	29
526	Pregnancy Differentially Impacts Performance of Latent Tuberculosis Diagnostics in a High-Burden Setting. PLoS ONE, 2014, 9, e92308.	1.1	49
527	The Feasibility of the Interferon Gamma Release Assay and Predictors of Discordance with the Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in a Remote Aboriginal Community. PLoS ONE, 2014, 9, e111986.	1.1	13

#	Article	IF	CITATIONS
528	Cutaneous tuberculosis: diagnosis, histopathology and treatment - Part II. Anais Brasileiros De Dermatologia, 2014, 89, 545-555.	0.5	43
529	Follow-up Testing of Interferon-Gamma Release Assays Are Useful in Ankylosing Spondylitis Patients Receiving Anti-Tumor Necrosis Factor Alpha for Latent Tuberculosis Infection. Journal of Korean Medical Science, 2014, 29, 1090.	1.1	11
530	Diagnosis and treatment of latent tuberculosis infection. Journal of the Korean Medical Association, 2014, 57, 12.	0.1	4
531	Accuracy of the QuantiFERON-TB Gold in Tube for diagnosing tuberculosis in a young pediatric population previously vaccinated with Bacille Calmette-Guerin. Revista Paulista De Pediatria, 2014, 32, 04-10.	0.4	10
532	Screening travellers to high-endemic countries for infection with Mycobacterium tuberculosis using interferon gamma release assay; a prospective study. BMC Infectious Diseases, 2014, 14, 515.	1.3	9
533	QuantiFERON-TB Gold In-Tube test conversions and reversions among tuberculosis patients and their household contacts in Addis Ababa: a one year follow-up study. BMC Infectious Diseases, 2014, 14, 654.	1.3	9
534	Ability of preventive therapy to cure latent <i>Mycobacterium tuberculosis</i> infection in HIV-infected individuals in high-burden settings. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5325-5330.	3.3	49
535	The Usefulness of the Tuberculosis Skin Test and the Interferon-gamma Release Assay in the Diagnosis of Latent Tuberculosis Infection in South Korea. Osong Public Health and Research Perspectives, 2014, 5, S18-S23.	0.7	3
536	High Proportion of Indeterminate Qua.jpegERON-TB Gold In-Tube Results in an Inpatient Population Is Related to Host Factors and Preanalytical Steps. Open Forum Infectious Diseases, 2014, 1, ofu088.	0.4	18
537	Update on cutaneous tuberculosis. Anais Brasileiros De Dermatologia, 2014, 89, 925-938.	0.5	61
538	Targeted Screening for Latent TB Infection prior to Biologic Therapy to Improve Patient Safety and Reduce Costs: A Prospective Observational Study. ISRN Infectious Diseases, 2014, 2014, 1-6.	0.5	0
539	Immunological Responses and Epitope Mapping by Tuberculosis-Associated Antigens within the RD1 Region in Japanese Patients. Journal of Immunology Research, 2014, 2014, 1-8.	0.9	9
540	RNA Interference-Based Therapeutics: Molecular Platforms for Infectious Diseases. Journal of Biomedical Nanotechnology, 2014, 10, 1998-2037.	0.5	22
541	Comparative Analysis of Assays for Detection of Cell-Mediated Immunity Toward Cytomegalovirus and M. tuberculosis in Samples From Deceased Organ Donors. American Journal of Transplantation, 2014, 14, 2159-2167.	2.6	25
542	<i>Ex-vivo</i> whole blood secretion of interferon (IFN)-Î ³ and IFN-Î ³ -inducible protein-10 measured by enzyme-linked immunosorbent assay are as sensitive as IFN-Î ³ enzyme-linked immunospot for the detection of gluten-reactive T cells in human leucocyte antigen (HLA)-DQ2·5+-associated coeliac disease. Clinical and Experimental Immunology, 2014, 175, 305-315.	1,1	50
543	Interferon-Î ³ Release Assays for Diagnosis of Tuberculosis Infection and Disease in Children. Pediatrics, 2014, 134, e1763-e1773.	1.0	142
544	Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIVâ€negative people at risk of active TB. Evidence-Based Child Health: A Cochrane Review Journal, 2014, 9, 169-294.	2.0	19
545	Long-term IFN-Î ³ and IL-2 response for detection of latent tuberculosis infection in healthcare workers with discordant immunologic results. Journal of Immunological Methods, 2014, 414, 51-57.	0.6	12

#	Article	IF	Citations
546	The Sensitivity of T-SPOT.TB Assay in Diagnosis of Pediatric Tuberculosis. Fetal and Pediatric Pathology, 2014, 33, 123-125.	0.4	4
547	Estimated Prevalence of Tuberculosis Infection Among a New York City Clinic Population Using Interferon-gamma Release Assays. Open Forum Infectious Diseases, 2014, 1, ofu047.	0.4	11
548	Congenital tuberculosis detected by T-SPOT.TB assay in a male infant after in vitro fertilization and followed up with radiography. Italian Journal of Pediatrics, 2014, 40, 96.	1.0	8
549	Performance of Interferon-gamma Release Assay for Tuberculosis Screening in Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases, 2014, 20, 2067-2072.	0.9	38
550	Tuberculous uveitis: an update. Expert Review of Ophthalmology, 2014, 9, 125-137.	0.3	4
551	Diagnostic Value of ELISPOT Technique for Osteoarticular Tuberculosis. Clinical Laboratory, 2014, 60, 1865-70.	0.2	7
552	Tuberculin Skin Tests versus Interferon-Gamma Release Assays in Tuberculosis Screening among Immigrant Visa Applicants. Tuberculosis Research and Treatment, 2014, 2014, 1-11.	0.2	4
553	Diagnosis of Latent Tuberculosis in Patients with Systemic Lupus Erythematosus: T.SPOT.TB <i>versus</i> Tuberculin Skin Test. BioMed Research International, 2014, 2014, 1-8.	0.9	12
554	Discordance of two interferon-γ release assays and tuberculin skin test in patients with uveitis. British Journal of Ophthalmology, 2014, 98, 1649-1653.	2.1	17
555	Prospective Head-to-Head Study Comparing 2 Commercial Interferon Gamma Release Assays for theÂDiagnosis of Tuberculous Uveitis. American Journal of Ophthalmology, 2014, 157, 1306-1314.e4.	1.7	34
556	Systematic review and meta-analysis on the utility of Interferon-gamma release assays for the diagnosis of Mycobacterium tuberculosis finfection in children: a 2013 update. BMC Infectious Diseases, 2014, 14, S6.	1.3	114
557	Interferon-gamma release assays for tuberculosis: current and future applications. Expert Review of Respiratory Medicine, 2014, 8, 67-78.	1.0	36
558	Performance of QuantiFERON-TB Gold and Tuberculin Skin Test Relative to Subjects' Risk of Exposure to Tuberculosis. Clinical Infectious Diseases, 2014, 58, 1260-1266.	2.9	26
559	Effective Tuberculosis and Hepatitis Screening Prior to Anti-TNF-α Therapy: Are We There Yet?. Digestive Diseases and Sciences, 2014, 59, 507-509.	1.1	3
560	Optimizing Screening for Tuberculosis and Hepatitis B Prior to Starting Tumor Necrosis Factor-α Inhibitors in Crohn's Disease. Digestive Diseases and Sciences, 2014, 59, 554-563.	1.1	15
561	IGRA-positive patients and interferon-gamma/interleukin-2 signatures: Can the Fluorospot assay provide further information?. Infection, 2014, 42, 539-543.	2.3	5
562	Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. Clinical Microbiology Reviews, 2014, 27, 3-20.	5.7	662
563	Whole blood assay and visceral leishmaniasis: Challenges and promises. Immunobiology, 2014, 219, 323-328.	0.8	21

#	Article	IF	CITATIONS
565	Cost effectiveness of interferon-Î ³ release assay for TB screening of HIV positive pregnant women in low TB incidence countries. Journal of Infection, 2014, 68, 32-42.	1.7	22
566	Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones. International Journal of Infectious Diseases, 2014, 18, 14-21.	1.5	55
567	Interferon-Î ³ release assay in the diagnosis of laryngeal tuberculosis. Acta Oto-Laryngologica, 2014, 134, 314-317.	0.3	8
568	Costâ€effectiveness of Using Quantiferon Gold (<scp>QFT</scp> â€G) [®] versus Tuberculin Skin Test (<scp>TST</scp>) among U.S. and Foreign Born Populations at a Public Health Department Clinic with a Low Prevalence of Tuberculosis. Public Health Nursing, 2014, 31, 144-152.	0.7	14
569	Safety of the two-step tuberculin skin test in Indian health care workers. International Journal of Mycobacteriology, 2014, 3, 247-251.	0.3	7
570	Pre-employment screening of latent tuberculosis infection among healthcare workers using tuberculin skin test and QuantiFERON-TB Gold test at a tertiary care hospital in Saudi Arabia. Journal of Infection and Public Health, 2014, 7, 481-488.	1.9	13
571	Interferonâ€gamma release assays and the diagnosis of tuberculosis: have they found their place?. Internal Medicine Journal, 2014, 44, 624-632.	0.5	7
572	Health Maintenance and Inflammatory Bowel Disease. Current Gastroenterology Reports, 2014, 16, 402.	1.1	13
573	Pre-placement screening for tuberculosis in healthcare workers. Occupational Medicine, 2014, 64, 524-529.	0.8	2
574	An evaluation of the use of a negative interferon-Î ³ release assay for tuberculosis screening before TNF antagonist therapy. European Respiratory Journal, 2014, 44, 1369-1372.	3.1	4
575	Use of interferon gamma release assays in clinical practice: Review of QuantiFERON-TB prescription in a French university hospital. Scandinavian Journal of Infectious Diseases, 2014, 46, 392-396.	1.5	3
576	Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes and Endocrinology,the, 2014, 2, 740-753.	5.5	154
577	The ongoing challenge of latent tuberculosis. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130437.	1.8	250
578	Herbalists, traditional healers and pharmacists: a view of the tuberculosis in Ghana. Revista Brasileira De Farmacognosia, 2014, 24, 89-95.	0.6	23
579	A Bayesian framework for estimating the incremental value of a diagnostic test in the absence of a gold standard. BMC Medical Research Methodology, 2014, 14, 67.	1.4	20
580	Tuberculosis screening at the Sainte-Anne Hospital in Paris – results of first and second IGRA. Journal of Occupational Medicine and Toxicology, 2014, 9, 24.	0.9	7
582	Nuclear imaging: A powerful novel approach for tuberculosis. Nuclear Medicine and Biology, 2014, 41, 777-784.	0.3	28
583	Synergistic antigen combinations for the development of interferon gamma release assays for paucibacillary leprosy. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 1415-1424.	1.3	15

#	Article	IF	CITATIONS
584	Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants. Journal of Virological Methods, 2014, 196, 157-162.	1.0	18
585	Performance of the Tuberculin Skin Test and Interferon-Â Release Assays: An Update on the Accuracy, Cutoff Stratification, and New Potential Immune-based Approaches. Journal of rheumatology Supplement, The, 2014, 91, 24-31.	2.2	80
586	Differences in immune cell function between tuberculosis positive and negative Asian elephants. Tuberculosis, 2014, 94, 374-382.	0.8	10
587	Tuberculosis vaccines – rethinking the current paradigm. Trends in Immunology, 2014, 35, 387-395.	2.9	109
588	Systematic review with metaâ€analysis: Accuracy of interferonâ€gamma releasing assay and antiâ€ <i><scp>S</scp>accharomyces cerevisiae</i> antibody in differentiating intestinal tuberculosis from <scp>C</scp> rohn's disease in <scp>A</scp> sians. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1664-1670.	1.4	66
589	The Microbiota in Infl ammatory Bowel Disease. , 2014, , 187-203.		Ο
590	Latent Tuberculosis Screening Using Interferon-Gamma Release Assays in an Australian HIV-Infected Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 48-54.	0.9	16
591	Increased Risk of Mycobacterium tuberculosis Infection in Household Child Contacts Exposed to Passive Tobacco Smoke. Pediatric Infectious Disease Journal, 2014, 33, 1303-1306.	1.1	8
592	Added value of interferon-gamma release assays in screening for tuberculous infection in the Netherlands. International Journal of Tuberculosis and Lung Disease, 2014, 18, 413-420.	0.6	22
593	Importancia del escrutinio para tuberculosis previo a la administración de agentes anti-TNF-α en uveÃŧis: a propósito de un caso clÂnico. Revista Mexicana De OftalmologÃa, 2014, 88, 194-199.	0.1	0
594	A TB Antigen-Stimulated CXCR3 Ligand Assay for the Diagnosis of Active Pulmonary TB. Chest, 2014, 146, 283-291.	0.4	18
595	Effect of Isoniazid Therapy for Latent TB Infection on QuantiFERON-TB Gold In-Tube Responses in Adults With Positive Tuberculin Skin Test Results in a High TB Incidence Area. Chest, 2014, 145, 612-617.	0.4	37
596	Comparison of the 2-step tuberculin skin test and QuantiFERON-TB Gold in-Tube test in the screening of latent tuberculosis infection in cancer patients. The Egyptian Journal of Chest Diseases and Tuberculosis, 2015, 64, 681-688.	0.1	3
597	Mycobacteriumdiagnostics: from the primitive to the promising. British Journal of Biomedical Science, 2015, 72, 32-41.	1.2	9
599	Tuberculosis screening programme for undocumented immigrant teenagers using the QuantiFERON®-TB Gold In-Tube test. Medicina ClÃnica (English Edition), 2015, 145, 7-13.	0.1	4
600	Comparative study of concordance and costs between tuberculin skin test and QuantiFERON®-TB Gold In-Tube in the diagnosis of latent tuberculosis infection among contacts of patients with pulmonary tuberculosis. Medicina ClÃnica (English Edition), 2015, 145, 427-432.	0.1	0
602	Performance of an interferon-gamma release assay in the diagnosis of tuberculous meningitis in children / Performanţa testului bazat pe eliberarea interferonului gamma în diagnosticul meningitei tuberculoase la copil. Romanian Journal of Laboratory Medicine, 2015, 23, .	0.1	3
603	Body Fluid Interferon-Î ³ Release Assay for Diagnosis of Extrapulmonary Tuberculosis in Adults: A Systematic Review and Meta-Analysis. Scientific Reports, 2015, 5, 15284.	1.6	29

#	Article	IF	Citations
604	Diagnosing Latent Tuberculosis in Immunocompromised Patients Measuring Blood IP-10 Production Capacity: An Analysis of Chronic Renal Failure Patients. Internal Medicine, 2015, 54, 465-472.	0.3	6
606	The 100 top-cited tuberculosis research studies. International Journal of Tuberculosis and Lung Disease, 2015, 19, 717-722.	0.6	26
607	Evaluating Indeterminate Interferonâ€Ĵ³â€"Release Assay Results in Patients With Chronic Inflammatory Diseases Receiving Immunosuppressive Therapy. Arthritis Care and Research, 2015, 67, 1063-1069.	1.5	14
608	Missed Opportunity to Prevent Tuberculosis. American Journal of Public Health, 2015, 105, e3-e3.	1.5	0
609	Epidemiology and clinical management of tuberculosis in children in Canada. Paediatrics and Child Health, 2015, 20, 83-88.	0.3	11
610	Recent Progress in Diagnosis Methods for Latent Tuberculosis Infection and Its Clinical Applications. Infection International, 2015, 4, 69-74.	0.1	0
611	Tuberculin skin test positivity without tuberculosis contact: A major challenge in childhood. Journal of Paediatrics and Child Health, 2015, 51, 632-638.	0.4	4
612	Superior Sensitivity of Ex Vivo IFN-Î ³ Release Assays as Compared to Skin Testing in Immunocompromised Patients. American Journal of Transplantation, 2015, 15, 2616-2624.	2.6	14
613	Detecting latent tuberculosis in compromised patients. Current Opinion in Infectious Diseases, 2015, 28, 275-282.	1.3	13
614	Tuberculosis Vaccine Development $\hat{a} {\in} "$ Its History and Future Directions. , 2015, , .		4
615	QuantiFERON-TB Gold In-Tube Assay for Screening Arthritis Patients for Latent Tuberculosis Infection before Starting Anti-Tumor Necrosis Factor Treatment. PLoS ONE, 2015, 10, e0119260.	1.1	25
616	Risk of Active Tuberculosis in HIV-Infected Patients in Taiwan with Free Access to HIV Care and a Positive T-Spot.TB Test. PLoS ONE, 2015, 10, e0125260.	1.1	6
617	A Serum Vitamin D Level <25nmol/L Pose High Tuberculosis Risk: A Meta-Analysis. PLoS ONE, 2015, 10, e0126014.	1.1	61
618	Accuracy of QuantiFERON-TB Gold Test for Tuberculosis Diagnosis in Children. PLoS ONE, 2015, 10, e0138952.	1.1	37
620	A 68-Year-Old Woman with Recurrent Cystitis. Canadian Journal of Infectious Diseases and Medical Microbiology, 2015, 26, e59-e61.	0.7	0
621	Chronic Pneumonia. , 2015, , 860-873.e2.		0
622	Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response. Journal of Clinical Investigation, 2015, 125, 1827-1838.	3.9	154
623	Evaluation of the usefulness of interferonâ€gamma release assays and the tuberculin skin test for the detection of latent <i>Mycobacterium tuberculosis</i> infections in Korean rheumatic patients who are candidates for biologic agents. International Journal of Rheumatic Diseases, 2015, 18, 315-322.	0.9	9

#	Article	IF	CITATIONS
624	In vitro immunomodulation for enhancing T cell–based diagnosis of Mycobacterium tuberculosis infection. Diagnostic Microbiology and Infectious Disease, 2015, 83, 41-45.	0.8	0
625	Feasibility of the interferon-gamma enzyme-linked immunospot assay in chronic renal failure patients and immunocompetent subjects: a head-to-head comparison. Renal Failure, 2015, 37, 203-208.	0.8	0
626	Mycobacterium tuberculosis-specific CD4 T cells are the principal source of IFN-Î ³ in QuantiFERON assays in healthy persons. Tuberculosis, 2015, 95, 350-351.	0.8	12
627	Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study. Lancet Infectious Diseases, The, 2015, 15, 310-319.	4.6	168
628	The Dynamics of QuantiFERON-TB Gold In-Tube Conversion and Reversion in a Cohort of South African Adolescents. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 584-591.	2.5	108
629	Cost-effectiveness of interferon-gamma release assay for systematic tuberculosis screening of healthcare workers in low-incidence countries. Journal of Hospital Infection, 2015, 89, 99-108.	1.4	12
630	Author's response: BCG and infection with Mycobacterium tuberculosis. Thorax, 2015, 70, 286-287.	2.7	0
631	Serial QuantiFERON-TB Gold In-Tube testing for psoriatic patients receiving antitumor necrosis factor-alpha therapy. Dermatologica Sinica, 2015, 33, 124-129.	0.2	12
633	Identification of Mycobacterium tuberculosis PPE68-Specific HLA-A*0201-Restricted Epitopes for Tuberculosis Diagnosis. Current Microbiology, 2015, 70, 769-778.	1.0	8
634	Coâ€evolution of <i><scp>M</scp>ycobacterium tuberculosis</i> and <i><scp>H</scp>omo sapiens</i> . Immunological Reviews, 2015, 264, 6-24.	2.8	244
635	Performance of a Rapid Strip Test for the Serologic Diagnosis of Latent Tuberculosis in Children. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, DC11-4.	0.8	1
636	Infectious complications in children with acute lymphoblastic leukemia treated in low-middle-income countries. Expert Review of Hematology, 2015, 8, 627-645.	1.0	27
637	Potential Benefits of Cattle Vaccination as a Supplementary Control for Bovine Tuberculosis. PLoS Computational Biology, 2015, 11, e1004038.	1.5	28
638	Mycobacterium bovis infection in the lion (Panthera leo): Current knowledge, conundrums and research challenges. Veterinary Microbiology, 2015, 177, 252-260.	0.8	24
639	Comparison of tuberculin skin test and QuantiFERON®â€TB Gold Inâ€Tube for the diagnosis of childhood tuberculosis. Pediatrics International, 2015, 57, 893-896.	0.2	5
640	Interferon-Î ³ Release Assay vs. Tuberculin Skin Test for Tuberculosis Screening in Exposed Healthcare Workers: A Longitudinal Multicenter Comparative Study. Infection Control and Hospital Epidemiology, 2015, 36, 569-574.	1.0	10
641	Role of QuantiFERON [®] -TB Gold In-Tube in tuberculosis contact investigation: experience in a tuberculosis unit. Infectious Diseases, 2015, 47, 244-251.	1.4	7
642	<scp>T</scp> â€ <scp>S</scp> pot. <scp><i>TB</i></scp> outperforms tuberculin skin test in predicting development of active tuberculosis among household contacts. Respirology, 2015, 20, 496-503.	1.3	11

#	Article	IF	CITATIONS
643	Latent Tuberculosis Infection Screening in Immigrants to Low-Incidence Countries: A Meta-Analysis. Molecular Diagnosis and Therapy, 2015, 19, 107-117.	1.6	30
644	The risk of tuberculosis in patients with psoriasis treated with antiâ€ŧumor necrosis factor agents. International Journal of Dermatology, 2015, 54, 594-599.	O.5	22
645	IFN-γ/TNF-α ratio in response to immuno proteomically identified human T-cell antigens of Mycobacterium tuberculosis – The most suitable surrogate biomarker for latent TB infection. Journal of Infection, 2015, 71, 238-249.	1.7	34
646	The T-SPOT.TB Test for Diagnosis of Breast Tuberculosis. Laboratory Medicine, 2015, 46, 14-19.	0.8	5
647	Could inducible protein-10 and heparin-binding hemagglutinin improve the detection of Mycobacterium tuberculosis-infected subjects in a country with low incidence of tuberculosis ?. Infectious Diseases, 2015, 47, 563-567.	1.4	2
648	Infection Prevention and the Medical Director. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 863-874.	2.2	8
649	The assessment of cytokines in Quantiferon supernatants for the diagnosis of latent TB infection in a tribal population of Melghat, India. Journal of Infection and Public Health, 2015, 8, 329-340.	1.9	11
650	Increased detection of latent tuberculosis by tuberculin skin test and booster phenomenon in early rheumatoid arthritis patients. Rheumatology International, 2015, 35, 1555-1559.	1.5	14
651	Screening and Vaccinations in Patients Requiring Systemic Immunosuppression: An Update for Dermatologists. American Journal of Clinical Dermatology, 2015, 16, 179-195.	3.3	11
653	Challenging Mycobacterium tuberculosis dormancy mechanisms and their immunodiagnostic potential. Brazilian Journal of Infectious Diseases, 2015, 19, 636-642.	0.3	8
654	Risk factors for false-negative T-SPOT.TB assay results in patients with pulmonary and extra-pulmonary TB. Journal of Infection, 2015, 70, 367-380.	1.7	56
655	Advances in Diagnostic Assays for Tuberculosis. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a017806.	2.9	13
656	Spontaneous Packaging and Hypothermic Storage of Mammalian Cells with a Cell-Membrane-Mimetic Polymer Hydrogel in a Microchip. ACS Applied Materials & Interfaces, 2015, 7, 23089-23097.	4.0	24
657	Early detection of Toxoplasma gondii-infected cats by interferon-gamma release assay. Experimental Parasitology, 2015, 157, 145-149.	0.5	13
658	Poncet's disease with high titers of rheumatoid factor and anti-citrullinated peptide antibodies mimicking rheumatoid arthritis. Journal of Infection and Chemotherapy, 2015, 21, 65-69.	0.8	11
659	Prevalence of latent tuberculosis infection in BCG-vaccinated healthcare workers by using an interferon-gamma release assay and the tuberculin skin test in an intermediate tuberculosis burden country. Journal of Microbiology, Immunology and Infection, 2015, 48, 147-152.	1.5	29
661	Prevention of Anti-Tumor Necrosis Factor-Associated Tuberculosis: A 10-Year Longitudinal Cohort Study. Clinical Infectious Diseases, 2015, 60, 349-356.	2.9	34
662	Mycobacterium tuberculosis. , 2015, , 1637-1653.		2

#	Article	IF	CITATIONS
663	Screening of latent tuberculosis infection by interferon-Î ³ release assays in rheumatic patients: a systemic review and meta-analysis. Clinical Rheumatology, 2016, 35, 417-425.	1.0	35
664	Clinical and Laboratory Diagnosis of Intestinal Tuberculosis. Chinese Medical Journal, 2016, 129, 1330-1333.	0.9	36
665	Assessment and monitoring of biologic drug adverse events in patients with psoriasis. Psoriasis: Targets and Therapy, 2016, 6, 41.	1.2	3
666	Impact of correcting the lymphocyte count to improve the sensitivity of TB antigen-specific peripheral blood-based quantitative T cell assays (T-SPOT.®TB and QFT-GIT). Journal of Thoracic Disease, 2016, 8, 482-489.	0.6	3
667	Pulmonary Tuberculosis Diagnosis: Where We Are?. Tuberculosis and Respiratory Diseases, 2016, 79, 134.	0.7	22
668	Combined Expression of IFN-γ, IL-17, and IL-4 mRNA by Recall PBMCs Moderately Discriminates Active Tuberculosis from Latent Mycobacterium tuberculosis Infection in Patients with Miscellaneous Inflammatory Underlying Conditions. Frontiers in Immunology, 2016, 7, 239.	2.2	6
669	Cost analysis of tuberculin skin test and the QuantiFERON-TB Gold In-tube test for tuberculosis screening in a correctional setting in Dallas, Texas, USA. BMC Infectious Diseases, 2016, 16, 564.	1.3	18
670	The Use of Interferon Gamma Inducible Protein 10 as a Potential Biomarker in the Diagnosis of Latent Tuberculosis Infection in Uganda. PLoS ONE, 2016, 11, e0146098.	1.1	32
671	Combined Analysis of IFN-γ, IL-2, IL-5, IL-10, IL-1RA and MCP-1 in QFT Supernatant Is Useful for Distinguishing Active Tuberculosis from Latent Infection. PLoS ONE, 2016, 11, e0152483.	1.1	53
672	Added Value of Long-Term Cytokine Release Assays to Detect Mycobacterium tuberculosis Infection in HIV-Infected Subjects in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 344-352.	0.9	5
673	Poor agreement between diagnostic tests for latent tuberculosis infection among HIVâ€infected persons in Hong Kong. Respirology, 2016, 21, 1322-1329.	1.3	8
674	Accuracy of the Bronchoalveolar Lavage Enzyme-Linked Immunospot Assay for the Diagnosis of Pulmonary Tuberculosis. Medicine (United States), 2016, 95, e3183.	0.4	7
675	Immunological Tests in Tuberculosis. , 0, , 433-443.		0
676	Treatment outcome in patients with presumed tubercular uveitis at a tertiary referral eye care centre in Singapore. International Ophthalmology, 2016, 38, 11-18.	0.6	8
677	Tuberculosis exposure, infection and disease in children: a systematic diagnostic approach. Pneumonia (Nathan Qld), 2016, 8, 23.	2.5	59
678	Cost-effectiveness of interferon-gamma release assays for tuberculosis screening in nursing homes. Epidemiology and Infection, 2016, 144, 3215-3225.	1.0	8
679	Diabetes mellitus and latent tuberculosis infection: a systemic review and meta-analysis. Clinical Infectious Diseases, 2017, 64, ciw836.	2.9	84
680	Prevention and Management of Tuberculosis in Transplant Recipients. Transplantation, 2016, 100, 1840-1852.	0.5	40

#	Article	IF	CITATIONS
681	Interferon-Gamma Release Assays and Pediatric Public Health Tuberculosis Screening: The San Francisco Program Experience 2005 to 2008. Journal of the Pediatric Infectious Diseases Society, 2016, 5, 122-130.	0.6	23
683	Interferon-Gamma Release Assays for the Diagnosis of Tuberculosis: A Systematic Review and Meta-analysis. Lung, 2016, 194, 447-458.	1.4	42
684	Ocular manifestations of tuberculosis: an update. Expert Review of Ophthalmology, 2016, 11, 145-154.	0.3	12
685	Multidrug-resistant tuberculosis outbreak in an Italian prison: tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays. New Microbes and New Infections, 2016, 12, 45-51.	0.8	6
686	Reactivation tuberculosis: role of surveillance. Expert Review of Anti-Infective Therapy, 2016, 14, 501-509.	2.0	2
687	Infectious Diseases (ID) Learning Unit: How Rapidly to Evaluate for Active Tuberculosis Disease in Low-Prevalence Settings. Open Forum Infectious Diseases, 2016, 3, ofw058.	0.4	1
688	PET/CT imaging of Mycobacterium tuberculosis infection. Clinical and Translational Imaging, 2016, 4, 131-144.	1.1	98
689	Preventative Care in the Patient with Inflammatory Bowel Disease: What Is New?. Digestive Diseases and Sciences, 2016, 61, 2205-2216.	1.1	9
690	Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults. JAMA - Journal of the American Medical Association, 2016, 316, 970.	3.8	66
691	Typical and Atypical Mycobacterium Infections After Hematopoietic Stem Cell or Solid Organ Transplantation. , 2016, , 381-395.		1
692	Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial. Clinical Microbiology and Infection, 2016, 22, 889.e9-889.e16.	2.8	30
693	Application of Mycobacterium Leprae -specific cellular and serological tests for the differential diagnosis of leprosy from confounding dermatoses. Diagnostic Microbiology and Infectious Disease, 2016, 86, 163-168.	0.8	12
694	Evaluation of interferonâ€gamma release assay (Tâ€SPOT.TB ^{â,,¢}) for diagnosis of tuberculosis infection in rheumatic disease patients. International Journal of Rheumatic Diseases, 2016, 19, 38-42.	0.9	10
695	Safety of Recombinant Fusion Protein ESAT6-CFP10 as a Skin Test Reagent for Tuberculosis Diagnosis: an Open-Label, Randomized, Single-Center Phase I Clinical Trial. Vaccine Journal, 2016, 23, 767-773.	3.2	15
696	Serial testing for latent tuberculosis using QuantiFERON-TB Gold In-Tube: A Markov model. Scientific Reports, 2016, 6, 30781.	1.6	27
697	Effects of acute critical illnesses on the performance of interferon-gamma release assay. Scientific Reports, 2016, 6, 19972.	1.6	14
698	The Role of Laboratory Tests in Crohn's Disease. Clinical Medicine Insights Gastroenterology, 2016, 9, CGast.S38203.	1.0	27
699	Cost effectiveness of interferon-gamma release assay for tuberculosis screening using three months of rifapentine and isoniazid among long-term expatriates from low to high incidence countries.	1.5	10

#	Article	IF	CITATIONS
700	Performance of interferon-Î ³ release assays in the diagnosis of confirmed active tuberculosis in immunocompetent children: a new systematic review and meta-analysis. BMC Infectious Diseases, 2016, 16, 131.	1.3	39
701	Diagnostic â€~omics' for active tuberculosis. BMC Medicine, 2016, 14, 37.	2.3	70
702	Isoniazid therapy for <1>Mycobacterium tuberculosis 1 infection in HIV clinics, Los Angeles, California. International Journal of Tuberculosis and Lung Disease, 2016, 20, 961-966.	0.6	4
703	The source of Mycobacterium tuberculosis-specific IFN-Î ³ production in peripheral blood mononuclear cells of TB patients. International Immunopharmacology, 2016, 32, 39-45.	1.7	6
704	Screening for Latent Tuberculosis in the Patient With Moderate to Severe Psoriasis Who Is a Candidate for Systemic and/or Biologic Therapy. Actas Dermo-sifiliográficas, 2016, 107, 207-214.	0.2	2
705	The pros and cons of the QuantiFERON test for the diagnosis of tuberculosis, prediction of disease progression, and treatment monitoring. International Journal of Mycobacteriology, 2016, 5, 177-184.	0.3	22
706	Despistaje de tuberculosis latente en el paciente con psoriasis moderada grave candidato a terapia sistémica y/o biológica. Actas Dermo-sifiliográficas, 2016, 107, 207-214.	0.2	5
707	The Prevalence of Latent Tuberculosis Infection in the United States. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 501-509.	2.5	79
708	The complexity of diagnosing latent tuberculosis infection in older adults in long-term care facilities. International Journal of Infectious Diseases, 2016, 44, 37-43.	1.5	11
709	First independent evaluation of QuantiFERON-TB Plus performance. European Respiratory Journal, 2016, 47, 1587-1590.	3.1	87
710	Methods Used in Economic Evaluations of Tuberculin Skin Tests and Interferon Gamma Release Assays for the Screening of Latent Tuberculosis Infection: A Systematic Review. Value in Health, 2016, 19, 267-276.	0.1	8
711	Guidelines for the use of interferon-γ release assays in the diagnosis of tuberculosis infection. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 303.e1-303.e13.	0.3	13
712	Utility of QuantiFERON-TB Gold In-Tube Test in the Diagnosis of Latent TB in HIV-Positive Patients in a Medium-TB Burden Country. Journal of the International Association of Providers of AIDS Care, 2016, 15, 101-106.	0.6	3
713	Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax, 2016, 71, 64-72.	2.7	77
714	Interferon-gamma release assay versus tuberculin skin test for latent tuberculosis infection among HIV patients in Brazil. Brazilian Journal of Infectious Diseases, 2016, 20, 69-75.	0.3	19
715	InÂvitro QuantiFERON-TB gold antigen specific interleukin-1beta to diagnose TB among HIV-positive subjects. Tuberculosis, 2016, 96, 27-30.	0.8	5
716	Laboratory Tests in Crohn's Disease. , 2016, , 15-30.		0
717	Tuberculose latente em profissionais de saúde: concordância entre 2 testes diagnósticos. Revista Portuguesa De Saude Publica, 2016, 34, 3-10.	0.3	3

#	Article	IF	CITATIONS
718	False-positive QuantiFERON TB-Gold test due to Mycobacterium gordonae. Diagnostic Microbiology and Infectious Disease, 2016, 84, 315-317.	0.8	5
719	No added value of interferon- \hat{I}^3 release to a prediction model for childhood tuberculosis. European Respiratory Journal, 2016, 47, 223-232.	3.1	9
720	Evaluation of heat shock proteins for discriminating between latent tuberculosis infection and active tuberculosis: A preliminary report. Journal of Infection and Public Health, 2016, 9, 143-152.	1.9	24
721	Predictive factors for treatment failure in patients with presumed ocular tuberculosis in an area of low endemic prevalence. British Journal of Ophthalmology, 2016, 100, 348-355.	2.1	37
723	Microbiological laboratory diagnostics of neglected zoonotic diseases (NZDs). Acta Tropica, 2017, 165, 40-65.	0.9	23
724	The Long-term Effect of Bacille Calmette-Guérin Vaccination on TuberculinÂSkin Testing. Chest, 2017, 152, 282-294.	0.4	45
725	C-Tb: a latent tuberculosis skin test for the 21st century?. Lancet Respiratory Medicine,the, 2017, 5, 236-237.	5.2	6
726	Pulmonary Tuberculosis: Role of Radiology in Diagnosis and Management. Radiographics, 2017, 37, 52-72.	1.4	219
727	<scp>CD</scp> 137 is a Useful Marker for Identifying <scp>CD</scp> 4 ⁺ T Cell Responses to <i>Mycobacterium tuberculosis</i> . Scandinavian Journal of Immunology, 2017, 85, 372-380.	1.3	15
728	Tuberculosis elimination and the challenge of latent tuberculosis. Presse Medicale, 2017, 46, e13-e21.	0.8	48
729	Attenuation of lymphocyte immune responses during Mycobacterium avium complex-induced lung disease due to increasing expression of programmed death-1 on lymphocytes. Scientific Reports, 2017, 7, 42004.	1.6	34
730	Controversies in ocular tuberculosis. British Journal of Ophthalmology, 2017, 101, 6-9.	2.1	57
731	<i>Mycobacterium kansasii</i> . Microbiology Spectrum, 2017, 5, .	1.2	37
732	Diagnosis of Latent Tuberculosis Infection. Microbiology Spectrum, 2017, 5, .	1.2	5
733	Glomerulonephritis Associated with Other Bacterial Infections. , 2017, , 63-85.		1
734	Novel Electrochemiluminescence-Sensing Platform for the Precise Analysis of Multiple Latent Tuberculosis Infection Markers. ACS Applied Materials & Interfaces, 2017, 9, 18493-18500.	4.0	29
735	Tuberculin skin test and interferon-gamma release assay use among privately insured persons in the United States. International Journal of Tuberculosis and Lung Disease, 2017, 21, 684-689.	0.6	4
736	Diagnostic dilemma in tuberculous pleural effusion. The Egyptian Journal of Chest Diseases and Tuberculosis, 2017, 66, 327-330.	0.1	0

#	Article	lF	CITATIONS
737	Identification and evaluation of the novel immunodominant antigen Rv2351c from Mycobacterium tuberculosis. Emerging Microbes and Infections, 2017, 6, 1-8.	3.0	7
738	Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis. BMC Medicine, 2017, 15, 104.	2.3	19
739	Efficacy of screening and treatment of latent tuberculosis infection. Mathematical Population Studies, 2017, 24, 21-36.	0.8	1
740	Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and meta-analysis. BMC Infectious Diseases, 2017, 17, 200.	1.3	106
741	Low vaccination rates among patients with rheumatoid arthritis in a German outpatient clinic. Rheumatology International, 2017, 37, 229-237.	1.5	43
742	The Tuberculosis Network European Trials Group (TBNET): new directions in the management of tuberculosis. Breathe, 2017, 13, e65-e71.	0.6	3
743	La tuberculose œsophagienne : à propos d'une nouvelle observation et revue de la littérature. Journal Africain D'Hepato-Gastroenterologie, 2017, 11, 187-189.	0.0	1
744	CTL immunogenicity of Rv3615c antigen and diagnostic performances of an ESAT-6/CFP-10/Rv3615c antigen cocktail for Mycobacterium tuberculosis infection. Tuberculosis, 2017, 107, 5-12.	0.8	5
745	Identification of mycobacterial bacterioferritin B for immune screening of tuberculosis and latent tuberculosis infection. Tuberculosis, 2017, 107, 119-125.	0.8	8
746	Analysis of Factors Influencing Diagnostic Accuracy of T-SPOT.TB for Active Tuberculosis in Clinical Practice. Scientific Reports, 2017, 7, 7764.	1.6	11
747	Immunological characterization of latent tuberculosis infection in a low endemic country. Tuberculosis, 2017, 106, 62-72.	0.8	12
748	A two-step algorithm for rapid diagnosis of active pulmonary tuberculosis in entry applicants using the T-SPOT.TB and Xpert MTB/RIF assays in Shanghai, China. Emerging Microbes and Infections, 2017, 6, 1-3.	3.0	2
749	PET/CT for differentiating between tuberculous peritonitis and peritoneal carcinomatosis. Medicine (United States), 2017, 96, e5867.	0.4	23
750	Tuberculosis State Is Associated with Expression of Toll-Like Receptor 2 in Sputum Macrophages. MSphere, 2017, 2, .	1.3	2
751	Tuberculosis "the great imitator― False healing and subclinical activity. Indian Journal of Tuberculosis, 2017, 64, 345-348.	0.3	2
752	QFT-Plus: a plus in variability? – Evaluation of new generation IGRA in serial testing of students with a migration background in Germany. Journal of Occupational Medicine and Toxicology, 2017, 12, 1.	0.9	40
753	The top-cited systematic reviews/meta-analyses in tuberculosis research. Medicine (United States), 2017, 96, e4822.	0.4	28
754	Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis. Tuberculosis, 2017, 106, 38-43.	0.8	89

#	Article	IF	CITATIONS
755	Mycobacteria. , 2017, , 1645-1659.e2.		3
756	Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious cases. Clinical Microbiology and Infection, 2017, 23, 147-153.	2.8	60
757	Diagnosis of tuberculous pleurisy with combination of adenosine deaminase and interferon-Î ³ immunospot assay in a tuberculosis-endemic population. Medicine (United States), 2017, 96, e8412.	0.4	15
758	Latent Tuberculosis Infection Screening Acceptability among Migrant Farmworkers. International Migration, 2017, 55, 62-74.	0.8	3
759	Tuberculous uveitis: association between anti-tuberculous therapy and clinical response in a non-endemic country. Journal of Ophthalmic Inflammation and Infection, 2017, 7, 19.	1.2	12
760	Diagnosis of Latent Tuberculosis Infection. , 0, , 59-66.		0
761	Evaluation of a New IFN-γ Release Assay for Rapid Diagnosis of Active Tuberculosis in a High-Incidence Setting. Frontiers in Cellular and Infection Microbiology, 2017, 7, 117.	1.8	25
762	Deconvolution of the Response to Bacillus Calmette–Guérin Reveals NF-κB-Induced Cytokines As Autocrine Mediators of Innate Immunity. Frontiers in Immunology, 2017, 8, 796.	2.2	25
763	Screening for Tuberculosis in Health Care Workers: Experience in an Italian Teaching Hospital. BioMed Research International, 2017, 2017, 1-6.	0.9	15
764	Utility of Th1-cell immune responses for distinguishing active tuberculosis from non-active tuberculosis: A case-control study. PLoS ONE, 2017, 12, e0177850.	1.1	6
765	QuantiFERON®-TB Gold In-Tube for contact screening in BCG-vaccinated adults: A longitudinal cohort study. PLoS ONE, 2017, 12, e0183258.	1.1	7
766	Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to Canada. PLoS ONE, 2017, 12, e0186778.	1.1	15
767	Assessment of the QuantiFERON-TB Gold In-Tube test for the detection of Mycobacterium tuberculosis infection in United States Navy recruits. PLoS ONE, 2017, 12, e0177752.	1.1	11
768	ORFeome-based identification of biomarkers for serodiagnosis of Mycobacterium tuberculosis latent infection. BMC Infectious Diseases, 2017, 17, 793.	1.3	9
769	Is IPT more effective in high-burden settings? Modelling the effect of tuberculosis incidence on IPT impact. International Journal of Tuberculosis and Lung Disease, 2017, 21, 60-66.	0.6	25
770	Modern Tools for Diagnosis in Tuberculous Ascites. , 2017, , .		1
771	Tuberculosis in Travelers and Immigrants. , 2017, , 356-370.		4
772	Diagnostic Significance of Mycobacterium tuberculosis T-cell Assays for Active Tuberculosis. Chinese Medical Journal, 2017, 130, 811-816.	0.9	2

ARTICLE IF CITATIONS The incidence of tuberculosis infection in hematopoietic stem cell transplantation recipients: A 773 0.7 11 retrospective cohort study from a center in Turkey. Transplant Infectious Disease, 2018, 20, e12912. Prospective Comparison of QFT-GIT and T-SPOT.TB Assays for Diagnosis of Active Tuberculosis. 774 1.6 Scientific Reports, 2018, 8, 5882. IGRA-Based Screening for Latent Tuberculosis Infection in Persons Newly Incarcerated in New York 775 0.2 8 City Jails. Journal of Correctional Health Care, 2018, 24, 156-170. Tuberculin skin test versus interferonâ€gamma release assay in refugee children: A retrospective cohort study. Journal of Paediatrics and Child Health, 2018, 54, 834-839. The interplay between tuberculosis and systemic lupus erythematosus. Current Opinion in 777 2.0 35 Rheumatology, 2018, 30, 395-402. Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731775220. Screening for latent tuberculosis infection among patients with rheumatoid arthritis in the era of biologics and targeted synthetic diseaseâ€modifying antiâ€rheumatic drugs in India, a highâ€burden 779 0.9 12 <scp>TB</scp> country: The importance of Mantoux and Quantiferonâ€<scp>TB</scp> Cold tests. International Journal of Rheumatic Diseases, 2018, 21, 1563-1571. Prevalence of positive QuantiFERON gold in-tube testing in hidradenitis suppurativa. Journal of 1.1 Dermatological Treatment, 2018, 29, 637-640. Potential Immunological Biomarkers for Detection of Mycobacterium tuberculosis Infection in a 781 1.0 12 Setting Where M. tuberculosis Is Endemic, Ethiopia. Inféction and Immunity, 2018, 86, . Evaluation of Mycobacterium tuberculosis-specific antibody responses for the discrimination of 1.5 active and latent tuberculosis infection. International Journal of Infectious Diseases, 2018, 70, 1-9. Low conversion rate of QuantiFERON-TB Gold screening tests in patients treated with tumor necrosis factor inhibitors: AÂretrospective cohort study identifying an important practiceÂgap. Journal of the 783 12 0.6 American Academy of Dermatology, 2018, 79, 169-171. Evaluation of risk factors for false-negative results with an antigen-specific peripheral blood-based quantitative T cell assay (T-SPOT[®].<i>TB</i>) in the diagnosis of active tuberculosis: A 784 0.4 large-scale retrospective study in China. Journal of International Medical Research, 2018, 46, 1815-1825. Diagnosis of Ocular Tuberculosis. Ocular Immunology and Inflammation, 2018, 26, 208-216. 785 1.0 49 More significance of <scp>TB</scp>â€<scp>IGRA</scp> except for the diagnose of tuberculosis. Journal of Clinical Laboratory Analysis, 2018, 32, . GradDock: rapid simulation and tailored ranking functions for peptide-MHC Class I docking. 787 1.8 34 Bioinformatics, 2018, 34, 469-476. Evaluating UK National Guidance for Screening of Children for Tuberculosis. A Prospective 2.5 Multicenter Study. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1058-1064. Sensitivity and specificity of QuantiFERON-TB Gold Plus compared with QuantiFERON-TB Gold In-Tube 789 0.8 65 and T-SPÓT.TB on active tuberculosis in Japan. Journal of Infection and Chemotherapy, 2018, 24, 188-192. Assessing and screening for T-cell epitopes from Mycobacterium tuberculosis RD2 proteins for the 790 diagnosis of active tuberculosis. Brazilian Journal of Infectious Diseases, 2018, 22, 462-471.

#	Article	IF	CITATIONS
791	Comparative sensitivity of the test with tuberculosis recombinant allergen, containing ESAT6-CFP10 protein, and Mantoux test with 2 TU PPD-L in newly diagnosed tuberculosis children and adolescents in Moscow. PLoS ONE, 2018, 13, e0208705.	1.1	23
792	Screening of latent tuberculosis infection among health care workers working in Hajj pilgrimage area in Saudi Arabia, using interferon gamma release assay and tuberculin skin test. Annals of Saudi Medicine, 2018, 38, 90-96.	0.5	14
793	Interferon-Gamma Release Assay is Not Appropriate for the Diagnosis of Active Tuberculosis in High-Burden Tuberculosis Settings. Chinese Medical Journal, 2018, 131, 268-275.	0.9	14
794	Characterization of specific CD4 and CD8 T-cell responses in QuantiFERON TB Gold-Plus TB1 and TB2 tubes. Tuberculosis, 2018, 113, 239-241.	0.8	11
795	The impact of migration on tuberculosis in the United States. International Journal of Tuberculosis and Lung Disease, 2018, 22, 1392-1403.	0.6	32
796	The Prevalence and Risk Factors of Latent Tuberculosis Infection among Health Care Workers Working in a Tertiary Hospital in South Korea. Tuberculosis and Respiratory Diseases, 2018, 81, 274.	0.7	21
797	Pharmacist perceptions of the New Mexico pharmacist-performed tuberculosis testing program. Journal of the American Pharmacists Association: JAPhA, 2018, 58, 647-651.	0.7	5
798	A Systematic Review on Novel Mycobacterium tuberculosis Antigens and Their Discriminatory Potential for the Diagnosis of Latent and Active Tuberculosis. Frontiers in Immunology, 2018, 9, 2476.	2.2	70
800	Predictors for false-negative QuantiFERON-TB Gold assay results in patients with extrapulmonary tuberculosis. BMC Infectious Diseases, 2018, 18, 457.	1.3	41
801	B cells response directed against Cut4 and CFP21 lipolytic enzymes in active and latent tuberculosis infections. PLoS ONE, 2018, 13, e0196470.	1.1	4
802	Interferon-gamma release assay performance in northeastern Brazil: influence of the IFNG+ 874 A>T polymorphism. Brazilian Journal of Infectious Diseases, 2018, 22, 202-207.	0.3	2
803	Borderline QuantiFERON results and the distinction between specific responses and test variability. Tuberculosis, 2018, 111, 102-108.	0.8	14
804	Risk factors associated with the development of active tuberculosis among patients with advanced chronic kidney disease. Journal of Infection, 2018, 77, 291-295.	1.7	18
805	QuantiFERON-TB Gold In-tube test for the diagnosis of active and latent tuberculosis in selected health facilities of Addis Ababa, Ethiopia. BMC Research Notes, 2018, 11, 293.	0.6	2
806	Tuberculin skin test and QuantiFERON-Gold In Tube assay for diagnosis of latent TB infection among household contacts of pulmonary TB patients in high TB burden setting. PLoS ONE, 2018, 13, e0199360.	1.1	30
807	Evaluating latent tuberculosis infection diagnostics using latent class analysis. Thorax, 2018, 73, 1062-1070.	2.7	36
808	Prevalence and risk factors of latent tuberculosis among Korean healthcare workers using whole-blood interferon-γ release assay. Scientific Reports, 2018, 8, 10113.	1.6	24
809	A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases. Journal of Crobn's and Colitis, 2018, 12, 954-962	0.6	25

#	Article	IF	Citations
810	Baseline Cytokine Profiles of Tuberculin-Specific CD4+ T Cells in Non–Muscle-Invasive Bladder Cancer May Predict Outcomes of BCG Immunotherapy. Cancer Immunology Research, 2018, 6, 1212-1219.	1.6	4
811	BCG: Its Impact on Tuberculosis and Relevance to Autoimmune Disease. , 2018, , 1-10.		1
812	Mycobacterium tuberculosis: Macrophage Takeover and Modulation of Innate Effector Responses. , 0, ,		7
813	Conventional and Molecular Diagnosis of Drug-Sensitive and Drug-Resistant Pulmonary Tuberculosis. , 2018, , .		1
814	Latent tuberculosis infection: Opportunities and challenges. Respirology, 2018, 23, 893-900.	1.3	63
815	Paradox of serial interferon-gamma release assays: variability width more important than specificity size. International Journal of Tuberculosis and Lung Disease, 2018, 22, 518-523.	0.6	4
816	Evaluation of a vaccination regimen and care in relation to follow-up and treatment of patients with inflammatory bowel disease. Revista De GastroenterologÃa De México (English Edition), 2019, 84, 11-17.	0.1	1
817	Correlation between the tuberculin skin test and T‑SPOT.TB in patients with suspected tuberculosis infection: A pilot study. Experimental and Therapeutic Medicine, 2019, 18, 2250-2254.	0.8	2
818	Evaluating Latent Tuberculosis Infection Test Performance Using Latent Class Analysis in a TB and HIV Endemic Setting. International Journal of Environmental Research and Public Health, 2019, 16, 2912.	1.2	11
819	Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy. Scientific Reports, 2019, 9, 11126.	1.6	13
820	The association between tuberculin skin test result and active tuberculosis risk of college students in Beijing, China: a retrospective cohort study. BMC Infectious Diseases, 2019, 19, 619.	1.3	15
821	Antimycobacterial Consideration in Transplantation Including Drug Non-susceptibility and Resistance: Tuberculosis and Nontuberculous Mycobacterial Disease. , 2019, , 1003-1017.		0
822	Genetic variants in IFNG and IFNGR1 and tuberculosis susceptibility. Cytokine, 2019, 123, 154775.	1.4	14
823	Medical care for migrant children in Europe: a practical recommendation for first and follow-up appointments. European Journal of Pediatrics, 2019, 178, 1449-1467.	1.3	29
824	The global prevalence of latent tuberculosis: a systematic review and meta-analysis. European Respiratory Journal, 2019, 54, 1900655.	3.1	314
825	Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2019, 74, 168.	0.2	1
826	ATBdiscrimination: An in Silico Tool for Identification of Active Tuberculosis Disease Based on Routine Blood Test and T-SPOT.TB Detection Results. Journal of Chemical Information and Modeling, 2019, 59, 4561-4568.	2.5	18
827	Application of IFN-γ/IL-2 FluoroSpot assay for distinguishing active tuberculosis from non-active tuberculosis: A cohort study. Clinica Chimica Acta, 2019, 499, 64-69.	0.5	3

#	Article	IF	CITATIONS
828	Evaluation of Varicellaâ€zoster virusâ€specific cellâ€mediated immunity by interferonâ€î3 Enzyme‣inked Immunosorbent Assay in adults ≥50 years of age administered a herpes zoster vaccine. Journal of Medical Virology, 2019, 91, 829-835.	2.5	3
829	Case 19-2019: A 38-Year-Old Woman with Abdominal Pain and Fever. New England Journal of Medicine, 2019, 380, 2461-2470.	13.9	1
830	The hidden hypothesis: A disseminated tuberculosis case. International Journal of Infectious Diseases, 2019, 85, 88-91.	1.5	0
831	Infections in Liver Transplantation. , 2019, , 41-72.		3
832	Comparison of Three Cellular Immunoassays to Detect Tuberculosis Infection in 876 Healthy Recruits. Journal of Interferon and Cytokine Research, 2019, 39, 547-553.	0.5	0
833	Discordance between the QuantiFERON Gold In-Tube and QuantiFERON Gold Plus assays associated with country of birth TB incidence. Tuberculosis, 2019, 116, S2-S10.	0.8	1
834	IFN-γ-independent immune markers of Mycobacterium tuberculosis exposure. Nature Medicine, 2019, 25, 977-987.	15.2	186
835	Latent tuberculosis infection in patients with rheumatic diseases. Jornal Brasileiro De Pneumologia, 2019, 45, e20190023.	0.4	24
836	Mycobacterial Infections in Patients With Chronic Kidney Disease and Kidney Transplantation. Advances in Chronic Kidney Disease, 2019, 26, 35-40.	0.6	15
837	Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries. Emerging Infectious Diseases, 2019, 25, 661-671.	2.0	19
838	Household fuel use and latent tuberculosis infection in a Nepali population. Environmental Research, 2019, 173, 69-76.	3.7	11
839	Accuracy of Commercial Molecular Diagnostics for the Detection of Pulmonary Tuberculosis in China: A Systematic Review. Scientific Reports, 2019, 9, 4553.	1.6	15
840	High rates of indeterminate interferonâ€gamma release assays for the diagnosis of latent tuberculosis infection in liver transplantation candidates. Transplant Infectious Disease, 2019, 21, e13087.	0.7	12
841	Nanoparticle-assisted optical sensor for clinical diagnosis of tuberculosis. Microchemical Journal, 2019, 147, 941-947.	2.3	6
842	Serial testing of Mycobacterium tuberculosis infection in Chinese village doctors by QuantiFERON-TB Gold Plus, QuantiFERON-TB Gold in-Tube and T-SPOT.TB. Journal of Infection, 2019, 78, 305-310.	1.7	15
843	Tuberculin skin test – Outdated or still useful for Latent TB infection screening?. International Journal of Infectious Diseases, 2019, 80, S20-S22.	1.5	26
844	Cost-effectiveness of QuantiFERON-TB Gold In-Tube versus tuberculin skin test for diagnosis and treatment of Latent Tuberculosis Infection in primary health care workers in Brazil. PLoS ONE, 2019, 14, e0225197.	1.1	8
845	Immune Biomarkers for Diagnosis and Treatment Monitoring of Tuberculosis: Current Developments and Future Prospects. Frontiers in Microbiology, 2019, 10, 2789.	1.5	66

ARTICLE IF CITATIONS Infectious Diseases among Refugee Children. Children, 2019, 6, 129. 0.6 16 846 Diagnostic Tests for Latent Tuberculosis Infection. Clinics in Chest Medicine, 2019, 40, 829-837. 847 0.8 Transcriptional Profiling of Human Peripheral Blood Mononuclear Cells Identifies Diagnostic 848 2.2 32 Biomarkers That Distinguish Active and Latent Tuberculosis. Frontiers in Immunology, 2019, 10, 2948. The T-SPOT.TB assay used for screening and monitoring of latent tuberculosis infection in patients with Behçet's disease pre- and post-anti-TNF treatment. Journal of the Chinese Medical Association, 849 2019, 82, 375-380. Reprogramming of Small Noncoding RNA Populations in Peripheral Blood Reveals Host Biomarkers for 850 1.8 28 Latent and Active Mycobacterium tuberculosis Infection. MBio, 2019, 10, . A diagnostic approach for differentiating abdominal tuberculosis from ovarian malignancy: a case 1.8 series and literature review. BMC Proceedings, 2019, 13, 13. Clinical utility of existing and second-generation interferon-Î³ release assays for diagnostic evaluation 852 4.6 47 of tuberculosis: an observational cohort study. Lancet Infectious Diseases, The, 2019, 19, 193-202. Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis. 2.1 American Journal of Kidney Diseases, 2019, 73, 39-50. EvaluaciÃ³n del esquema de vacunaciÃ³n y cuidados con relaciÃ³n al seguimiento y tratamiento de los 854 pacientes con enfermedad inflamatoria intestinal. Revista De GastroenterologÃa De México, 2019, 84, 0.4 1 11-17. Mycobacterium tuberculosis: <scp>A</scp>ctive disease and latent infection in a renal transplant cohort. Nephrology, 2019, 24, 569-574. Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS) – Report 2: Pattern of Uveitis 856 2 1.0 Investigations in Singapore. Ocular Immunology and Inflammation, 2020, 28, 92-99. Current Practices in Ocular Tuberculosis: A Survey of Brazilian Specialists. Ocular Immunology and 1.0 Inflammation, 2020, 28, 256-261. Reproducibility of the T-SPOT.TB test for screening Mycobacterium tuberculosis infection in Japan. 858 0.8 3 Journal of Infection and Chemotherapy, 2020, 26, 194-198. Effectiveness of BCG Vaccination Against Mycobacterium tuberculosis Infection in Adults: A 1.9 29 Cross-sectional Analysis of a UK-Based Cohort. Journal of Infectious Diseases, 2020, 221, 146-155. Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. 860 2.57 American Journal of Respiratory and Critical Care Medicine, 2020, 201, 598-605. Host factors associated to false negative and indeterminate results in an interferonâ€i³ release assay in 1.0 23 patients with active tuberculosis. Pulmonology, 2020, 26, 353-362. Clinical application of QuantiFERON-TB Gold in-tube in the diagnosis and treatment of tuberculosis. 863 1.36 European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 607-612. Preventive tuberculosis treatment effect on QuantiFERON TB-Gold in-tube testing in a high 864 tuberculosis-endemic country: A clinical trial. International Journal of Infectious Diseases, 2020, 91, 1.5 182-187.

#	Article	IF	CITATIONS
865	An RNA-seq Based Machine Learning Approach Identifies Latent Tuberculosis Patients With an Active Tuberculosis Profile. Frontiers in Immunology, 2020, 11, 1470.	2.2	25
866	Newer diagnostic tests for tuberculosis, their utility, and their limitations. Current Medicine Research and Practice, 2020, 10, 8-11.	0.1	8
867	Combining interferon- γ release assays with lymphocyte enumeration for diagnosis of <i>Mycobacterium tuberculosis</i> infection. Journal of International Medical Research, 2020, 48, 030006052092566.	0.4	4
868	Prevalence of Latent Tuberculosis Infection Among Non-US-Born Persons by Country of Birth—United States, 2012–2017. Clinical Infectious Diseases, 2021, 73, e3468-e3475.	2.9	9
869	Mycobacterial EST12 activates a RACK1–NLRP3–gasdermin D pyroptosis–IL-1β immune pathway. Science Advances, 2020, 6, .	4.7	62
870	Diagnosis for Latent Tuberculosis Infection: New Alternatives. Frontiers in Immunology, 2020, 11, 2006.	2.2	95
871	Evaluation of digital PCR assay in detection of M.tuberculosis IS6110 and IS1081 in tuberculosis patients plasma. BMC Infectious Diseases, 2020, 20, 657.	1.3	14
872	Cost-effectiveness of newer technologies for the diagnosis of Mycobacterium tuberculosis infection in Brazilian people living with HIV. Scientific Reports, 2020, 10, 21823.	1.6	9
873	Comparing the Diagnostic Performance of QuantiFERON-TB Gold Plus to Other Tests of Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2021, 73, e1116-e1125.	2.9	27
874	Higher T-SPOT.TB threshold may aid in diagnosing active tuberculosis?: A real-world clinical practice in a general hospital. Clinica Chimica Acta, 2020, 509, 60-66.	0.5	4
875	Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology. Frontiers in Immunology, 2020, 11, 316.	2.2	59
876	Cost-effectiveness of IGRA/QFT-Plus for TB screening of migrants in Oman. International Journal of Infectious Diseases, 2020, 92, S72-S77.	1.5	14
877	Risk Analysis of Latent Tuberculosis Infection among Health Workers Compared to Employees in Other Sectors. International Journal of Environmental Research and Public Health, 2020, 17, 4643.	1.2	6
878	Tuberculin skin test positivity among HIV-infected alcohol drinkers on antiretrovirals in south-western Uganda. PLoS ONE, 2020, 15, e0235261.	1.1	5
879	Risk of Occupational Latent Tuberculosis Infection among Health Personnel Measured by Interferon-Gamma Release Assays in Low Incidence Countries—A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health, 2020, 17, 581.	1.2	17
880	Screening and treatment of tuberculosis among pregnant women in Stockholm, Sweden, 2016–2017. European Respiratory Journal, 2020, 55, 1900851.	3.1	8
881	High reproducibility of the interferon-gamma release assay T-SPOT.TB in serial testing. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 85-93.	1.3	2
882	QuantiFERON®-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Guérin (BCG)-vaccinated country: the HUR-BIO single-center real-life results. Clinical Rheumatology, 2021, 40, 2027-2035.	1.0	4

#	Article	IF	CITATIONS
883	Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study. Journal of Korean Medical Science, 2021, 36, e70.	1.1	7
884	Features of indeterminate results of QuantiFERON-TB Gold In-Tube test in patients with haematological malignancies. Therapeutic Advances in Hematology, 2021, 12, 204062072110284.	1.1	5
885	Tuberculosis in Pediatric Solid Organ and Hematopoietic Stem Cell Recipients. Global Pediatric Health, 2021, 8, 2333794X2098154.	0.3	1
886	Association between erythema nodosum/erythema induratum of Bazin and <i>Mycobacterium tuberculosis</i> infection in Koreans. Indian Journal of Dermatology, Venereology and Leprology, 2021, 88, 196-200.	0.2	1
888	Screening for TB in Hospitalised Patients with Inflammatory Bowel Disease before Anti-TNF Therapy: Is QuantiFERON® Gold Testing Useful?. Journal of Clinical Medicine, 2021, 10, 1816.	1.0	3
889	Impact of T-Cell Xtend on T-SPOT. TB Assay in High-Risk Individuals after Delayed Blood Sample Processing. Journal of Clinical Microbiology, 2021, 59, .	1.8	1
890	Latent Tuberculosis Infection Status of Pregnant Women in Uganda Determined Using QuantiFERON TB Gold-Plus. Open Forum Infectious Diseases, 2021, 8, ofab241.	0.4	7
891	A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease. Frontiers in Immunology, 2021, 12, 661622.	2.2	14
892	Human tuberculosis and Mycobacterium tuberculosis complex: A review on genetic diversity, pathogenesis and omics approaches in host biomarkers discovery. Microbiological Research, 2021, 246, 126674.	2.5	55
893	Mycobacterium tuberculosis in solid organ transplant donors and recipients. Current Opinion in Organ Transplantation, 2021, 26, 432-439.	0.8	6
894	Diagnosing active tuberculosis in primary care. BMJ, The, 2021, 374, n1590.	3.0	4
895	TB Antigen-Stimulated CXCR3 Ligand Assay for Diagnosis of Tuberculous Lymphadenitis. International Journal of Environmental Research and Public Health, 2021, 18, 8020.	1.2	3
896	The Relationship between Pre-Pandemic Interferon Gamma Release Assay Test Results and COVID-19 Infection: Potential Prognostic Value of Indeterminate IFN-Î ³ Release Assay Results. Canadian Journal of Infectious Diseases and Medical Microbiology, 2021, 2021, 1-9.	0.7	4
897	Increased Expression of IL-10 in Peripheral Blood Mononuclear Cells Correlates with Negative Interferon-1 ³ Release Assay Results in Culture-Confirmed Tuberculosis Patients. Infection and Drug Resistance, 2021, Volume 14, 3135-3143.	1.1	2
898	Cost-effectiveness of testing for latent tuberculosis infection in people with HIV. Aids, 2022, 36, 1-9.	1.0	4
899	Fewer losses in the cascade of care for latent tuberculosis with solo interferon-gamma release assay screening compared to sequential screening. BMC Infectious Diseases, 2021, 21, 936.	1.3	2
900	Prevalence of Latent Tuberculosis Infection Among Healthy Young Children and Adolescents and a Two-step Approach for the Diagnosis of Tuberculosis Infection in Chengdu, China. Pediatric Infectious Disease Journal, 2022, 41, 6-11.	1.1	3
901	The Tuberculosis Vaccine Development Pipeline: Present and Future Priorities and Challenges for Research and Innovation. , 2021, , 395-405.		4

#	Article	IF	CITATIONS
903	IL-7 Addition Increases Spot Size and Number as Measured by T-SPOT.TB ®. Methods in Molecular Biology, 2012, 792, 229-241.	0.4	7
904	Transplant Infections in Developing Countries. , 2016, , 129-150.		1
905	Differential Diagnosis of Inflammatory Bowel Disease. , 2017, , 199-209.		1
906	Main Complications of AECHB and Severe Hepatitis B (Liver Failure). , 2019, , 91-226.		1
907	Usefulness and limitations of QuantiFERON-TB Gold in Japanese rheumatoid arthritis patients: proposal to decrease the lower cutoff level for assessing latent tuberculosis infection. Modern Rheumatology, 2010, 20, 18-23.	0.9	8
908	Tuberculosis and other mycobacterial infections. , 2010, , 309-327.		20
909	Mycobacteria. , 2010, , 1777-1800.		1
910	Infections in Recipients of Hematopoietic Cell Transplantation. , 2010, , 3821-3837.		2
912	Mycobacterium tuberculosis. , 2012, , 771-786.e6.		4
913	Tuberculosis: Newer diagnostic tests: Applications and limitations. Indian Journal of Tuberculosis, 2020, 67, S86-S90.	0.3	8
914	Tuberculosis in children: New diagnostic blood tests. Paediatrics and Child Health, 2010, 15, 529-533.	0.3	15
915	Time Since Infection and Risks of Future Disease for Individuals with Mycobacterium tuberculosis Infection in the United States. Epidemiology, 2021, 32, 70-78.	1.2	16
916	Application of transdermal patches with new skin test reagents for detection of latent tuberculosis. Journal of Medical Microbiology, 2019, 68, 1314-1319.	0.7	4
917	Whole blood interleukin-2 release test to detect and characterize rare circulating gluten-specific T cell responses in coeliac disease. Clinical and Experimental Immunology, 2021, 204, 321-334.	1.1	15
920	<i>Mycobacterium:</i> General Characteristics, Laboratory Detection, and Staining Procedures. , 0, , 536-569.		34
921	The Effectiveness of Using Interferon-gamma Release Assays in Screening Immigration Employees for Latent Tuberculosis Infection. International Journal of Occupational and Environmental Health, 2011, 17, 322-327.	1.2	1
922	Microbiology of Mycobacterium tuberculosis and a new diagnostic test for TB. , 2012, , 1-13.		4
923	What next? Basic research, new treatments and a patient-centred approach in controlling tuberculosis. , 0, , 414-429.		1

#	Article	IF	CITATIONS
925	Detection of Mycobacterium tuberculosis DNA in CD34+ peripheral blood mononuclear cells of Ugandan adults with latent infection: a cross-sectional and nested prospective study. AAS Open Research, 2020, 3, 34.	1.5	3
926	Evidence-Based Tuberculosis Diagnosis. PLoS Medicine, 2008, 5, e156.	3.9	72
927	Accuracy of Immunodiagnostic Tests for Active Tuberculosis Using Single and Combined Results: A Multicenter TBNET-Study. PLoS ONE, 2008, 3, e3417.	1.1	88
928	The Impact of HIV Infection and CD4 Cell Count on the Performance of an Interferon Gamma Release Assay in Patients with Pulmonary Tuberculosis. PLoS ONE, 2009, 4, e4220.	1.1	88
929	In Vivo and In Vitro Effects of Antituberculosis Treatment on Mycobacterial Interferon-Î ³ T Cell Response. PLoS ONE, 2009, 4, e5187.	1.1	48
930	Role of Interferon Gamma Release Assay in Active TB Diagnosis among HIV Infected Individuals. PLoS ONE, 2009, 4, e5718.	1.1	62
931	Tuberculosis Infection among Young Nursing Trainees in South India. PLoS ONE, 2010, 5, e10408.	1.1	52
932	Evaluation of the Prognostic Value of IFN-Î ³ Release Assay and Tuberculin Skin Test in Household Contacts of Infectious Tuberculosis Cases in Senegal. PLoS ONE, 2010, 5, e10508.	1.1	51
933	First-in-Man Open Clinical Trial of a Combined rdESAT-6 and rCFP-10 Tuberculosis Specific Skin Test Reagent. PLoS ONE, 2010, 5, e11277.	1.1	30
934	ls IP-10 an Accurate Marker for Detecting M. tuberculosis-Specific Response in HIV-Infected Persons?. PLoS ONE, 2010, 5, e12577.	1.1	73
935	Mycobacterium tuberculosis Lipolytic Enzymes as Potential Biomarkers for the Diagnosis of Active Tuberculosis. PLoS ONE, 2011, 6, e25078.	1.1	51
936	High Annual Risk of Tuberculosis Infection among Nursing Students in South India: A Cohort Study. PLoS ONE, 2011, 6, e26199.	1.1	32
937	Multiple Cytokines Are Released When Blood from Patients with Tuberculosis Is Stimulated with Mycobacterium tuberculosis Antigens. PLoS ONE, 2011, 6, e26545.	1.1	68
938	Strategies for Treating Latent Multiple-Drug Resistant Tuberculosis: A Decision Analysis. PLoS ONE, 2012, 7, e30194.	1.1	19
939	Repeat IGRA Testing in Canadian Health Workers: Conversions or Unexplained Variability?. PLoS ONE, 2013, 8, e54748.	1.1	63
940	Cost-Effectiveness of Quantiferon®-TB Cold-In-Tube Versus Tuberculin Skin Testing for Contact Screening and Treatment of Latent Tuberculosis Infection in Brazil. PLoS ONE, 2013, 8, e59546.	1.1	43
941	Mycobacterium tuberculosis Infection Is Associated with the Development of Erythema Nodosum and Nodular Vasculitis. PLoS ONE, 2013, 8, e62653.	1.1	24
942	Strategy to Better Select HIV-Infected Individuals for Latent TB Treatment in BCG-Vaccinated Population. PLoS ONE, 2013, 8, e73069.	1.1	15

# 943	ARTICLE Frequent Detection of Latent Tuberculosis Infection among Aged Underground Hard Coal Miners in the Absence of Recent Tuberculosis Exposure. PLoS ONE, 2013, 8, e82005.	IF 1.1	Citations
944	Interferon-Gamma Release Assay Performance of Pleural Fluid and Peripheral Blood in Pleural Tuberculosis. PLoS ONE, 2013, 8, e83857.	1.1	32
945	Discordance of Tuberculin Skin Test and Interferon Gamma Release Assay in Recently Exposed Household Contacts of Pulmonary TB Cases in Brazil. PLoS ONE, 2014, 9, e96564.	1.1	26
946	Tuberculin Skin Testing and Treatment Modulates Interferon-Gamma Release Assay Results for Latent Tuberculosis in Migrants. PLoS ONE, 2014, 9, e97366.	1.1	23
947	Comparing Interferon-Gamma Release Assays to Tuberculin Skin Test in Thai Children with Tuberculosis Exposure. PLoS ONE, 2014, 9, e105003.	1.1	17
948	Costs and Consequences of Using Interferon-Î ³ Release Assays for the Diagnosis of Active Tuberculosis in India. PLoS ONE, 2015, 10, e0124525.	1.1	13
949	Cough Aerosol Cultures of Mycobacterium tuberculosis: Insights on TST / IGRA Discordance and Transmission Dynamics. PLoS ONE, 2015, 10, e0138358.	1.1	16
950	Single-Cell Cytokine Gene Expression in Peripheral Blood Cells Correlates with Latent Tuberculosis Status. PLoS ONE, 2015, 10, e0144904.	1.1	6
951	Comparison of TST and IGRA in Diagnosis of Latent Tuberculosis Infection in a High TB-Burden Setting. PLoS ONE, 2017, 12, e0169539.	1.1	90
952	Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: A latent-class analysis. PLoS ONE, 2017, 12, e0188631.	1.1	63
953	Recommendations on Interferon Gamma Release Assaysfor the Diagnosis of Latent Tuberculosis Infection—2010 Update. Canada Communicable Disease Report, 2010, 36, 1-22.	0.6	23
954	Comparison of Results between Tuberculin Skin Test and QuantiFERON®-TB In-Tube Assay for Diagnosis of Latent Tuberculosis Infection in Children and Adolescents. Korean Journal of Pediatric Infectious Diseases, 2013, 20, 17.	0.1	4
956	Epidemiology of neglected tropical diseases in transplant recipients: review of the literature and experience of a Brazilian HSCT center. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2009, 51, 309-324.	0.5	58
957	Intestinal tuberculosis and Crohn�s disease: the importance and difficulty of a differential diagnosis. Revista Espanola De Enfermedades Digestivas, 2018, 110, 650-657.	0.1	16
958	Diagnostic tests: Testing for tuberculosis. Australian Prescriber, 2010, 33, 12-18.	0.5	78
959	Screening for tuberculosis infection in children and adolescents in Russia – past, present, future. Tuberculosis and Lung Diseases, 2019, 97, 59-66.	0.2	23
960	SCREENING FOR TUBERCULOSIS INFECTION IN CHILDREN AND ADOLESCENTS IN RUSSIA – PAST, PRESENT, FUTURE. Tuberculosis and Lung Diseases, 2019, 97, 59-67.	0.2	8
961	Diagnostic Accuracy of Monocyte Chemotactic Protein (MCP)-2 as Biomarker in Response to PE35/PPE68 Proteins: A Promising Diagnostic Method for the Discrimination of Active and Latent Tuberculosis. Protein and Peptide Letters, 2019, 26, 281-286.	0.4	7

#	Article	IF	CITATIONS
962	The Challenging Evaluation of Patients with Severe Psoriasis for Latent Tuberculosis: An Important Indication for IGRA. Open Respiratory Medicine Journal, 2011, 5, 59-60.	1.3	5
963	The challenge of pediatric tuberculosis in face of new diagnostic techniques. Jornal De Pediatria, 2009, 85, 183-193.	0.9	2
964	The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review. Eurosurveillance, 2018, 23, .	3.9	25
965	Assessing the effect of foreign travel and protection by BCG vaccination on the spread of tuberculosis in a low incidence country, United Kingdom, October 2008 to December 2009. Eurosurveillance, 2011, 16, .	3.9	14
966	Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation. Health Technology Assessment, 2016, 20, 1-678.	1.3	30
967	Interferon gamma release assays for Diagnostic Evaluation of Active tuberculosis (IDEA): test accuracy study and economic evaluation. Health Technology Assessment, 2019, 23, 1-152.	1.3	16
968	Clobal evidence directing regional preventive strategies in Southeast Asia for fighting TB/HIV. Journal of Infection in Developing Countries, 2013, 7, 191-202.	0.5	8
969	Comparing tuberculin skin test and interferon γ release assay (T-SPOT.TB) to diagnose latent tuberculosis infection in household contacts. Korean Journal of Internal Medicine, 2017, 32, 486-496.	0.7	2
970	Interferon-gamma-release assays: Better than tuberculin skin testing?. Cleveland Clinic Journal of Medicine, 2010, 77, 606-611.	0.6	5
971	Screening for latent tuberculosis infections at the beginning of hemodialysis in our hospital. Nihon Toseki Igakkai Zasshi, 2018, 51, 599-605.	0.2	1
972	Insight into the diagnosis and management of subclinical genital tuberculosis in women with infertility. Journal of Human Reproductive Sciences, 2016, 9, 135.	0.4	18
973	Tuberculous uveitis. Middle East African Journal of Ophthalmology, 2009, 16, 188-201.	0.5	22
974	Brain tuberculomas, tubercular meningitis, and post-tubercular hydrocephalus in children. Journal of Pediatric Neurosciences, 2011, 6, 96.	0.2	52
975	Mycobacterium tuberculosis pyomyositis in an infant. Annals of Medical and Health Sciences Research, 2013, 3, 282.	0.8	5
976	Prevalence of latent tuberculosis infection among tuberculosis laboratory workers in Iran. Epidemiology and Health, 2017, 39, e2017002.	0.8	10
977	What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 387.	0.6	6
978	Saudi guidelines for testing and treatment of latent tuberculosis infection. Annals of Saudi Medicine, 2010, 30, 38-49.	0.5	2
979	Screening for latent tuberculosis infection in patients with inflammatory bowel disease: Can interferon-gamma release assays replace the tuberculin skin test?. Turkish Journal of Gastroenterology, 2019, 29, 292-298.	0.4	5

#	Article	IF	CITATIONS
980	Comparison of QuantiFERON-TB gold in-tube test with tuberculin skin test in children who had no contact with active tuberculosis case. Tuberkuloz Ve Toraks, 2014, 62, 116-121.	0.2	7
981	Role of NK Cells in Tuberculous Pleurisy as Innate Promoters of Local Type 1 Immunity with Potential Application on Differential Diagnosis. , 0, , .		1
982	T-SPOT.TB for Detection of Tuberculosis Infection among Hematological Malignancy Patients and Hematopoietic Stem Cell Transplant Recipients. Asian Pacific Journal of Cancer Prevention, 2013, 14, 7415-7419.	0.5	18
983	Accuracy of the interferon-gamma release assay for the diagnosis of tuberculous pleurisy: an updated meta-analysis. PeerJ, 2015, 3, e951.	0.9	18
984	Evaluation of role of interferon gamma release assays in the diagnosis of latent tuberculosis in human immunodeficiency virus-infected patients. Indian Journal of Sexually Transmitted Diseases and AIDS, 2021, 42, 111.	0.1	2
985	The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease. Epidemiology, 2022, 33, 75-83.	1.2	2
986	A Pilot TB Screening Model in a U.S. Prison Population Using Tuberculin Skin Test and Interferon Gamma Release Assay Based on Country of Origin. Journal of Correctional Health Care, 2021, 27, 259-264.	0.2	0
987	Association of Vitamin D Receptor Polymorphism (rs2228570, rs1544410, rs7975232, and rs731236) and Macrophage Migration Inhibitory Factor -173 G/C (rs755622) with the Susceptibility of Active Pulmonary Tuberculosis in Makassar, Indonesia. Open Access Macedonian Journal of Medical Sciences, 2021. 9, 838-848.	0.1	0
991	Chronic Pneumonia. , 2010, , 931-945.		1
992	é«"æ¶²ã®QuantiFERON® TB-2GæææŸ»ã«ã,^ã,Šï¼Œçµæ,性髄膜ç,Žã,'早期ã«è™æ–ã§ãã¥ä,€ä¾<. Jo	urn al oof th	ie Japanese So
992 993	é«"æ¶²ã®QuantiFERON® TB-2GæææŸ»ã«ã, ã,Šï¼Œçµæ,性髄膜ç,Žã,'早期ã«è [™] æ—ã§ããŸä,€ä¾<. Jo La tuberculose chez les enfants : de nouvelles analyses sanguines diagnostiques. Paediatrics and Child Health, 2010, 15, 534-538.	urnæloof th 0.3	ie Japanese So O
	La tuberculose chez les enfants : de nouvelles analyses sanguines diagnostiques. Paediatrics and Child		
993	La tuberculose chez les enfants : de nouvelles analyses sanguines diagnostiques. Paediatrics and Child Health, 2010, 15, 534-538.		0
993 994	La tuberculose chez les enfants : de nouvelles analyses sanguines diagnostiques. Paediatrics and Child Health, 2010, 15, 534-538. Mycobacterium tuberculous Infection. , 2011, , 455-461. A CASE OF TUBERCULOUS ABSCESS IN THE CHEST WALL THAT WAS DIAGNOSED AFTER RESECTION. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2011, 72, 1112-1115.	0.3	0
9993 9994 9996	La tuberculose chez les enfants : de nouvelles analyses sanguines diagnostiques. Paediatrics and Child Health, 2010, 15, 534-538. Mycobacterium tuberculous Infection. , 2011, , 455-461. A CASE OF TUBERCULOUS ABSCESS IN THE CHEST WALL THAT WAS DIAGNOSED AFTER RESECTION. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2011, 72, 1112-1115.	0.3	0 0 0
9993 9994 9996 1000	La tuberculose chez les enfants : de nouvelles analyses sanguines diagnostiques. Paediatrics and Child Health, 2010, 15, 534-538. Mycobacterium tuberculous Infection., 2011,, 455-461. A CASE OF TUBERCULOUS ABSCESS IN THE CHEST WALL THAT WAS DIAGNOSED AFTER RESECTION. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2011, 72, 1112-1115. Mycobacterial Infections Associated with TNF-î± Inhibitors., 0,,.	0.3	0 0 0 0
993 994 996 1000	La tuberculose chez les enfants : de nouvelles analyses sanguines diagnostiques. Paediatrics and Child Health, 2010, 15, 534-538. Mycobacterium tuberculous Infection., 2011,, 455-461. A CASE OF TUBERCULOUS ABSCESS IN THE CHEST WALL THAT WAS DIAGNOSED AFTER RESECTION. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2011, 72, 1112-1115. Mycobacterial Infections Associated with TNF-α Inhibitors., 0, , . Interferon-gamma ELISPOT for the screening and diagnosis of latent tuberculosis infection in healthy population of China. Advances in Bioscience and Biotechnology (Print), 2012, 03, 259-268.	0.3	0 0 0 0 0

#	Article	IF	CITATIONS
1007	Comparison of the Tuberculin Skin Test and the Interferon-Î ³ Release Assay for the Diagnosis of Cervical Tuberculous Lymphadenitis. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2013, 56, 354.	0.0	3
1008	DOCUMENTO SOBRE O RASTREIO DA TUBERCULOSE EM PORTADORES DE DOENÇAS INFLAMATÓRIAS IMUNOMEDIADAS CANDIDATOS A TERAPÊUTICA BIOLÓGICA. Journal of the Portuguese Society of Dermatology and Venereology, 2013, 70, 435-448.	0.0	1
1009	Updating a Tuberculosis Surveillance Program: Considering All of the Variables. Workplace Health and Safety, 2013, 61, 271-278.	0.7	2
1010	TUBERCULOSIS THEN AND NOW: A REVIEW ON CONTINUING DIAGNOSTIC PROGRESS. Journal of Evolution of Medical and Dental Sciences, 2013, 2, 5923-5935.	0.1	0
1011	Economic Analysis of Latent Tuberculosis Infection Screening Strategies in Korea. Health Policy and Management, 2013, 23, 349-357.	0.3	0
1012	Research Progress in Detection Technology of Mycobacterium tuberculosis. Advances in Microbiology, 2014, 03, 64-69.	0.0	0
1013	Prevention of Infectious Diseases. , 2014, , 238-251.		0
1015	Mycobacterium Tuberculosis in New Biologic Era. Current Rheumatology Reviews, 2014, 9, 200-208.	0.4	0
1018	Systematic Reviews and Meta-analyses in Rheumatology. , 2014, , 229-246.		1
1019	Discordance between Two Interferon-Gamma Release Assays in the Diagnosis of Latent Tuberculosis Infection in Healthcare Workers. Journal of Infectious Disease and Therapy, 2014, 02, .	0.1	0
1020	Diagnosis and Management of Tuberculosis in Candidates for Tumor Necrosis Factor Alpha Antagonists: An Experts Survey. Mycobacterial Diseases: Tuberculosis & Leprosy, 2014, 04, .	0.1	1
1021	SPECIFIC IMMUNOLOGICAL TESTS IN DIAGNOSTICS OF TUBERCULOSIS OF GENITALS. Russian Journal of Infection and Immunity, 2014, 4, 207.	0.2	0
1022	The evolution and role of interferon gamma release assays (IGRAs) in moderate and low income settings HRM Scintilla, 2014, 4, 56.	0.0	0
1023	Infections in Recipients of Hematopoietic Stem Cell Transplants. , 2015, , 3425-3439.e5.		2
1024	Evaluation of the QuantiFERON®-TB Gold In-Tube assay and tuberculin skin test for the diagnosis of Mycobacterium tuberculosis infection in northeastern Thailand. Asian Pacific Journal of Allergy and Immunology, 2015, 33, 236-44.	0.2	3
1027	Discordance between Tuberculin Skin Test and Interferon Gamma Release Assay is Associated with Previous Latent Tuberculosis Infection Treatment. Mycobacterial Diseases: Tuberculosis & Leprosy, 2016, 06, .	0.1	0
1028	Significance and Challenges of Interferon Gamma Release Assay in Tuberculosis Infection Control. Japanese Journal of Environmental Infections, 2016, 31, 81-86.	0.1	0
1030	Tuberculin Skin Test and Interferon-γ Release Assays in the Diagnosis of Ocular Tuberculosis. Essentials in Ophthalmology, 2017, , 35-49.	0.0	0

#	Article	IF	Citations
1031	Latent Infection with Mycobacterium tuberculosis. , 2017, , 359-368.		0
1032	Mycobacterium kansasii. , 0, , 725-734.		2
1034	The Value of Diagnostic Work-Up in the Evaluation of White Dot Syndromes. Ophthalmic Surgery Lasers and Imaging Retina, 2017, 48, 540-545.	0.4	0
1036	Treatment of tuberculosis infection complicated with liver transplant. Infection International, 2018, 7, 81-87.	0.1	0
1037	Comparison of IFN-Î ³ Levels in Children with Tuberculosis Disease (TB) and Latent Tuberculosis Infection (LTBI). Open Access Macedonian Journal of Medical Sciences, 2018, 6, 2091-2096.	0.1	1
1038	IMMUNODIAGNOSTICS OF TUBERCULOSIS: 10-YEAR EXPERIENCE OF USING IMMUNOLOGICAL TESTS IN RUSSIA. Tuberculosis and Lung Diseases, 2019, 97, 58-65.	0.2	5
1039	Progress in interferon-gamma release assay development and applications: an unfolding story of translational research. Annals of Translational Medicine, 2019, 7, S128-S128.	0.7	2
1040	Latent tuberculosis infection in patients with autoimmune diseases treated with Infliximab and Etanercept. Infectio, 2019, 23, 371.	0.4	0
1042	Controversies and Pitfalls in the Diagnosis of Extrapulmonary Tuberculosis with a Focus on Genital Tuberculosis. US Endocrinology, 2020, 16, 109.	0.3	4
1043	The impact of blood transcriptomic biomarker targeted tuberculosis preventive therapy in people living with HIV: a mathematical modelling study. BMC Medicine, 2021, 19, 252.	2.3	4
1044	Bacterial and Fungal Diseases. , 2020, , 116-126.		0
1045	Utility of the monocyte to lymphocyte ratio in diagnosing latent tuberculosis among HIV-infected individuals with a negative tuberculosis symptom screen. PLoS ONE, 2020, 15, e0241786.	1.1	6
1046	Behçet's disease with latent Mycobacterium tuberculosis infection. Open Medicine (Poland), 2020, 16, 14-22.	0.6	3
1048	T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. International Journal of Tuberculosis and Lung Disease, 2009, 13, 84-92.	0.6	104
1049	The sensitivity of interferon-gamma release assays is not compromised in tuberculosis patients with diabetes. International Journal of Tuberculosis and Lung Disease, 2011, 15, 179-84, i-iii.	0.6	25
1050	Central nervous system tuberculosis. African Health Sciences, 2011, 11, 116-27.	0.3	107
1051	The MIT D-lab electricity-free PortaTherm™ incubator for remote testing with the QuantiFERON®-TB Gold In-Tube assay. International Journal of Tuberculosis and Lung Disease, 2010, 14, 1468-74.	0.6	9
1052	Low agreement between the T-SPOT®.TB assay and the tuberculin skin test among college students in China. International Journal of Tuberculosis and Lung Disease, 2011, 15, 134-6.	0.6	6

#	Article	IF	CITATIONS
1053	Prospective Comparison of Two Brands of Tuberculin Skin Tests and Quantiferon-TB Gold in-tube Assay Performances for Tuberculosis Infection in Hospitalized Children. Mædica, 2010, 5, 271-6.	0.4	5
1055	Crohn's disease: the subsequent visit. Gastroenterology and Hepatology, 2013, 9, 16-20.	0.2	2
1056	Fever of unknown origin: report of 107 cases in a university hospital. International Journal of Clinical and Experimental Medicine, 2014, 7, 5862-6.	1.3	6
1057	Close contact investigation of TB in high-burden, low- and middle-income countries. Malaysian Family Physician, 2014, 9, 11-7.	0.2	2
1058	QuantiFERON-TB Gold and Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Children. Iranian Journal of Medical Sciences, 2015, 40, 411-7.	0.3	4
1059	Differential diagnosis between Crohn's disease and intestinal tuberculosis using integrated parameters including clinical manifestations, T-SPOT, endoscopy and CT enterography. International Journal of Clinical and Experimental Medicine, 2015, 8, 17578-89.	1.3	12
1061	Screening of Latent Tuberculous Infection (LTBI) before starting anti-tumor necrosis factor therapy in patients with psoriasis: A primer for clinical dermatologist. Indian Journal of Dermatology, 2021, 66, 501.	0.1	1
1062	Effect of adjusted cut-offs of interferon-Î ³ release assays on diagnosis of tuberculosis in patients with fever of unknown origin. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2022, 26, 100290.	0.6	2
1063	Positive Rates of Interferon-Î ³ Release Assay and Tuberculin Skin Test in Detection of Latent Tuberculosis Infection: A Systematic Review and Meta-Analysis of 200,000 Head-to-Head Comparative Tests. SSRN Electronic Journal, 0, , .	0.4	0
1064	Role of Interferon-gamma release assay for the diagnosis and clinical follow up in ocular tuberculosis. Ocular Immunology and Inflammation, 2022, , 1-8.	1.0	1
1065	Biomarkers to identify <i>Mycobacterium tuberculosis</i> infection among borderline QuantiFERON results. European Respiratory Journal, 2022, 60, 2102665.	3.1	11
1066	Anti-TNFα et tuberculose. HEGEL - HEpato-GastroEntérologie Libérale, 2013, Nº 2, 106-115.	0.0	0
1067	Prevalence of Latent Tuberculous Infection in Patients With Nontuberculous Mycobacterial Lung Disease and Colonization: A Prospective Study in an Intermediate Tuberculosis Burden Country. Open Forum Infectious Diseases, 2022, 9, ofac072.	0.4	2
1068	In-hospital blood collection increases the rate of indeterminate results in interferon-gamma release assays. Therapeutic Advances in Respiratory Disease, 2022, 16, 175346662210778.	1.0	3
1069	Resistance to Mycobacterium tuberculosis infection among highly TB exposed South African gold miners. PLoS ONE, 2022, 17, e0265036.	1.1	10
1070	Chapter 4: Diagnosis of tuberculosis infection. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 49-65.	0.2	3
1071	Diagnostic Performance of a Novel CXCL10 mRNA Release Assay for Mycobacterium tuberculosis Infection. Frontiers in Microbiology, 2022, 13, 825413.	1.5	2
1072	Latent tuberculosis testing through the ages: the search for a sleeping killer. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2022, 322, L412-L419.	1.3	5

#	Article	IF	CITATIONS
1073	Impact of Immunosuppressive Therapy on the Performance of Latent Tuberculosis Screening Tests in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine, 2022, 12, 507.	1.1	9
1074	Latent Tuberculosis Infection. New England Journal of Medicine, 2021, 385, 2271-2280.	13.9	54
1079	Multiple Strictures of Small Intestine: Is It a Crohn's Disease?. Gastroenterology, 2022, , .	0.6	0
1080	Analysis of an Interferon-Gamma Release Assay for Monitoring the Efficacy of Anti-Tuberculosis Chemotherapy. Japanese Journal of Infectious Diseases, 2011, 64, 133-138.	0.5	6
1082	In Vitro and In Vivo Antigen Presentation and Diagnosis Development of Recombinant Overlapping Peptides Corresponding to Mtb ESAT-6/CFP-10. Frontiers in Immunology, 0, 13, .	2.2	3
1083	Interferon-Inducible Protein-10 as a Marker to Detect Latent Tuberculosis Infection in Patients with Inflammatory Rheumatic Diseases. Journal of Personalized Medicine, 2022, 12, 1027.	1.1	2
1084	Serial T-SPOT.TB responses in Tanzanian adolescents: Transient, persistent and irregular conversions. PLoS ONE, 2022, 17, e0268685.	1.1	1
1085	Analysis of Clinical Features and Risk Factors in Pregnant Women With Miliary Pulmonary Tuberculosis After In Vitro Fertilization Embryo Transfer. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	4
1086	Skin thickness affects the result of tuberculin skin test in systemic sclerosis. BMC Rheumatology, 2022, 6, .	0.6	0
1088	Evaluation of TB elimination strategies in Canadian Inuit populations: Nunavut as a case study. Infectious Disease Modelling, 2022, , .	1.2	0
1089	Are interferon-gamma release assays reliable to detect tuberculosis infection in patients with rheumatoid arthritis treated with Janus kinase inhibitors?. PLoS ONE, 2022, 17, e0275329.	1.1	2
1090	Testing and Treating Mycobacterium tuberculosis Infection. Medical Clinics of North America, 2022, 106, 929-947.	1.1	2
1092	Prevalence and risk factors of latent tuberculosis infection among college students: a systematic review and meta-analysis. Public Health, 2022, 213, 135-146.	1.4	2
1093	Tuberculosis – important issues to know. Medic Ro, 2022, 6, 17.	0.0	0
1094	Progress on diagnosis and treatment of latent tuberculosis infection. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences, 2022, 51, 691-696.	0.1	0
1095	Variance-based sensitivity analysis of tuberculosis transmission models. Journal of the Royal Society Interface, 2022, 19, .	1.5	0
1096	MANAGEMENT OF LATENT TUBERCULOSIS INFECTION BASED ON T-SPOT.TB ASSAY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES. Mediterranean Journal of Hematology and Infectious Diseases, 2023, 15, e2023003.	0.5	0
1097	Intracranial tuberculoma masquerading as a brain tumor: A rare presentation in a healthy young adult with no prior history of tuberculosis. IDCases, 2023, 31, e01700.	0.4	1

#	Article	IF	CITATIONS
1098	Assessing the Diagnostic Performance of New Commercial Interferon-Î ³ Release Assays for <i>Mycobacterium tuberculosis</i> Infection: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases, 2023, 76, 1989-1999.	2.9	5
1099	Differential Diagnosis of Inflammatory Bowel Disease. , 2023, , 217-228.		1
1101	Tuberculosis mimicking the onset of systemic lupus erythematosus flare: Case based review. International Journal of Rheumatic Diseases, 2023, 26, 1143-1148.	0.9	1
1102	Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection. Tropical Medicine and Infectious Disease, 2023, 8, 89.	0.9	3
1103	A cost-effectiveness evaluation of latent tuberculosis infection screening of a migrant population in Malaysia. Scientific Reports, 2023, 13, .	1.6	3
1119	Mycobacterium tuberculosis. , 2024, , 1569-1584.		0